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The Rad9-Rad1-Hus1 Complex and Bif-1 Regulate Multiple Mechanisms that Affect
Sensitivity to DNA Damage
Cheryl L. Meyerkord
ABSTRACT
The resistance of cancer cells to traditional chemotherapeutic agents is a major
obstacle in the successful treatment of cancer. Cancer cells manipulate a variety of
signaling pathways to enhance resistance to anticancer agents; such mechanisms include
disrupting the DNA damage response and hyperactivating survival signaling pathways. In
an attempt to better understand the molecular mechanisms that underlie resistance to
chemotherapeutic agents, we investigated multiple processes regulated by the Rad9Rad1-Hus1 (9-1-1) complex and Bif-1. The 9-1-1 complex plays an integral role in the
response to DNA damage and regulates many downstream signaling pathways.
Overexpression of members of this complex has been described in several types of cancer
and was shown to correlate with tumorigenicity. In this study, we demonstrate that
disruption of the 9-1-1 complex, through loss of Hus1, sensitizes cells to DNA damaging
agents by upregulating BH3-only protein expression. Moreover, loss of Hus1 results in
release of Rad9 into the cytosol, which enhances the interaction of Rad9 with Bcl-2 to
potentiate the apoptotic response. We also provide evidence that disruption of the 9-1-1
complex sensitizes cells to caspase-independent cell death in response to DNA damage.
Furthermore, we found that loss of Hus1 enhances DNA damage-induced autophagy. As
x

autophagy has been implicated in caspase-independent cell death, these data suggest that
the enhanced autophagy observed in Hus1-knockout cells may act as an alternate cell
death mechanism. However, inhibition of autophagy, through knockdown of Atg7 or Bif1, did not suppress, but rather promoted DNA damage-induced cell death in Hus1deficient cells, suggesting that in apoptosis-competent cells autophagy may be induced as
a cytoprotective mechanism. The aberrant activation of survival signals, such as
enhanced EGFR signaling, is another mechanism that provides cancer cells with
resistance to DNA damage. We found that knockdown of Bif-1 accelerated the colocalization of EGF with late endosomes/lysosomes thereby promoting EGFR
degradation. Our results suggest that Bif-1 may enhance survival not only by inducing
autophagy, but also by regulating EGFR degradation. Taken together, the results from
our studies indicate that the 9-1-1 complex and Bif-1 may be potential targets for cancer
therapy as they both regulate sensitivity to DNA damage.

xi

Chapter One: Introduction

Cancer
Despite major advances in the treatment of cancer, this disease is still the second
leading cause of death in the United States (Jemal et al., 2008). It is estimated that in
2008 over 1.4 million people were diagnosed with cancer and over 0.5 million people
died from this disease. Cancer is caused by both internal factors, such as inherited
mutations, and external factors, such as exposure to DNA damaging agents (American
Cancer Society, 2008). Tumorigenesis is a multi-step process that is characterized by the
accumulation of genetic mutations that transform normal cells into malignant derivatives
(Hanahan and Weinberg, 2000). These mutations can activate oncogenes and inactivate
tumor suppressor genes resulting in genomic instability and driving tumor progression.
Paradoxically, DNA-damaging agents are some of the most effective drugs used for the
treatment cancer. In addition, the efficacy of DNA damage-based chemotherapy may be
influenced by the ability of a cell to repair damaged DNA (Helleday et al., 2008).
Therefore, deciphering the cellular mechanisms that are activated in response to DNA
damage may not only lead to a better understanding of the causes of cancer, but also to
better, more effective treatment strategies.

1

The DNA Damage Response
The genomes of eukaryotic cells are constantly being subjected to endogenous
and exogenous genotoxic stresses. Damage resulting from exposure to such stresses
threatens cell survival and can lead to cancer, as well as other genetic diseases. In order to
preserve genomic integrity and ensure that an accurate copy of the genome is passed on
to subsequent generations, cells have evolved a core surveillance machinery that senses
damaged or abnormally structured DNA and coordinates cell cycle progression with
DNA repair. In cases when damage is excessive or repair is unfavorable, the cell death
machinery is activated in order to eliminate damaged cells (Melo and Toczyski, 2002;
Niida and Nakanishi, 2006; Zhou and Elledge, 2000).
In response to genotoxic stress, a complex network of interacting checkpoint
signaling pathways act in concert to execute an appropriate DNA damage response
(DDR) (Harper and Elledge, 2007). In mammalian cells, two related phosphatidylinositol
3-kinase-related serine/threonine kinases play a central role in the regulation of the DDR
(Abraham, 2001; Matsuoka et al., 2007). The ATM (ataxia-telangiectasia mutated)mediated pathway is activated in response to DNA damaging agents that induce doublestrand breaks (Lavin, 2008), whereas the ATR (ATM- and Rad3-related)-dependent
pathway responds to a broad spectrum of genotoxic stresses including those that inhibit
replication and induce single-strand DNA breaks or bulky DNA lesions (Cimprich and
Cortez, 2008).
Mutations in ATM lead to the autosomal recessive disorder ataxia-telangiectasia,
which is characterized by immunodeficiency, radiosensitivity, neurodegeneration and
cancer predisposition (Boder, 1985). Individuals, mice and cells that lack ATM are
2

viable, which indicates that ATM is not required for differentiation, normal cell cycle
progression or other essential cellular functions (Shiloh and Kastan, 2001). Under normal
conditions, ATM exists as an inactive homodimer. In response to DNA damage, ATM
undergoes a conformational change, which stimulates its kinase activity. ATM is then
autophosphorylated at serine 1981 leading to the dissociation of inactive homodimers to
form active monomers (Bakkenist and Kastan, 2003). DNA damage also induces the
association of ATM with the MRE11-Rad50-Nbs1 (MRN) complex, which acts as an
adaptor for the recruitment of downstream signaling proteins and facilitates the full
activation and proper localization of ATM (Berkovich et al., 2007; van den Bosch et al.,
2003). ATM-mediated phosphorylation of H2AX (γH2AX) recruits MDC1, which acts as
a positive feedback loop to facilitate further ATM phosphorylation of H2AX and the
recruitment of additional ATM-MRN complexes, thereby propagating the DDR (Stucki
and Jackson, 2006).
In contrast to ATM, ATR is required for viability (Brown and Baltimore, 2000);
however, hypomorphic mutations of ATR are associated with Seckel syndrome
(O'Driscoll et al., 2003). ATR is constitutively bound to ATRIP (ATR-interacting
protein) even in the absence of DNA damage or replicative stress (Cortez et al., 2001).
ATRIP binds to the single-stranded DNA-coating protein, RPA (replication protein A),
which facilitates the recruitment of ATR to DNA and the activation of downstream
signaling (Zou and Elledge, 2003). However, recruitment of ATR to the site of DNA
damage is not sufficient to activate ATR signaling, several other proteins must be present
in order for ATR to execute all of its cellular functions. Rad17, the Rad9-Rad1-Hus1 (91-1) complex, TopBP1 (topoisomerase-binding protein-1) and Claspin are all required for
3

the full activation of ATR-mediated downstream signaling (Chini and Chen, 2003;
Delacroix et al., 2007; Kumagai et al., 2006; Weiss et al., 2002; Zou et al., 2002). The
loading of the 9-1-1 complex onto the DNA results in the recruitment of TopBP1 through
its interaction with Rad9 (Delacroix et al., 2007; Lee et al., 2007). TopBP1 then binds to
the ATR-ATRIP complex and enhances the kinase activity of ATR (Kumagai et al.,
2006; Mordes et al., 2008).
Upon activation, ATM and ATR are responsible for relaying the DNA damage
signal to downstream transducer and effector proteins (Chen et al., 2001; Niida and
Nakanishi, 2006; Zou et al., 2002). ATM and ATR may regulate as many as 700
substrates in response to DNA damage (Matsuoka et al., 2007). While ATM and ATR
share some substrate specificity, these kinases have also been shown to selectively
phosphorylate different substrates (Cimprich and Cortez, 2008; Kim et al., 1999; Zhou
and Elledge, 2000). Two proteins that play a key role in conveying the DNA damage
response are the checkpoint proteins, Chk2 and Chk1, which are phosphorylated by ATM
and ATR, respectively. Along with ATM and ATR, Chk1 and Chk2 are responsible for
transducing the DNA damage signal to downstream effector proteins, such as p53,
MDM2, BRCA1, E2F1, Cdc25A and Cdc25C (Bartek and Lukas, 2003; Kastan and
Bartek, 2004). Through the phosphorylation of these, and many other proteins, ATM and
ATR respond to DNA damage in order to regulate cell cycle arrest/progression, facilitate
DNA repair, regulate transcriptional events and induce apoptosis (Zhou and Elledge,
2000) (Figure 1).
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Figure 1. Simplified schematic of the DNA damage response.

The Rad9-Rad1-Hus1 Complex
The members of the Rad (radiation sensitive) family are key regulators in sensing
DNA damage and regulating checkpoint activation (Parrilla-Castellar et al., 2004). In
fission yeast, certain members of the Rad family including Rad9, Rad1, Hus1, Rad17 and
Rad3 (ATR) are essential for both the DNA damage and DNA replication checkpoints
(Rhind and Russell, 1998). Evidence suggests that the functions of these proteins are
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conserved in mammals, which highlights the critical role for these proteins in the DDR
(Parrilla-Castellar et al., 2004).

Structure and Role in the DNA Damage Response
Three members of the Rad family, Rad9, Rad1 and Hus1, form a heterotrimeric
clamp that acts as a putative sensor for DNA damage (Burtelow et al., 2001; Hang and
Lieberman, 2000; Roos-Mattjus et al., 2002; St. Onge et al., 1999; Volkmer and Karnitz,
1999). Biochemical and molecular modeling data suggest that the 9-1-1 complex bears
structural similarity to the homotrimeric PCNA (proliferating cell nuclear antigen) sliding
clamp (Venclovas and Thelen, 2000), which is loaded onto DNA during replication,
recombination and repair (Tsurimoto, 1999). Another member of the Rad family, Rad17,
along with the four small subunits of the replication factor C complex (RFC), is
responsible for loading the 9-1-1 complex onto DNA in response to various types of
DNA damage (Bermudez et al., 2003; Lindsey-Boltz et al., 2001; Rauen et al., 2000)
(Figure 2). Together with Rad17, the 9-1-1 complex is responsible for facilitating ATRmediated signaling pathways that are required for an appropriate response to DNA
damage. While the 9-1-1 complex is required for full activation of the ATR-mediated
DDR, it appears to be dispensable for activation of the ATM-mediated pathway (Weiss et
al., 2002). However, it has been shown that ATM can phosphorylate Rad9 on serine 272.
This event is required for checkpoint activation in response to IR (Chen et al., 2001),
suggesting that 9-1-1- and ATM-mediated responses may not be completely exclusive.
Thus, the 9-1-1 complex collaborates with ATR and ATM to activate downstream
signaling pathways and cell cycle checkpoints.
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Figure 2. Comparison of the Rad9-Rad1-Hus1 complex and PCNA.
Unlike the other members of the 9-1-1 complex, Rad9 possesses a carboxyterminal region that is constitutively phosphorylated and inducibly hyperphosphorylated
in response to DNA damage (Chen et al., 2001; Roos-Mattjus et al., 2003; St Onge et al.,
2001; St Onge et al., 2003). While this region is not required for interaction with Rad17,
Rad1 or Hus1, it is required for Chk1 phosphorylation and downstream signaling (RoosMattjus et al., 2003). It has been suggested that the C-terminus of Rad9, in which the
“phospho-tail” is located, is responsible not only for translocation of the 9-1-1 complex to
the nucleus (through a nuclear localization signal) (Hirai and Wang, 2002), but also for
the recruitment of signaling proteins to DNA lesions, thereby facilitating the activation of
downstream signaling pathways (Roos-Mattjus et al., 2003).
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Regulation of DNA Repair
In addition to playing a central role in DDR signaling pathways, the 9-1-1
complex has also been shown to play a direct role in several DNA repair mechanisms. A
role for the 9-1-1 complex in base excision repair (BER) (especially long-patch BER) has
been well described (Helt et al., 2005). It has been shown that the 9-1-1 complex
regulates the early steps of BER by binding to and enhancing the activity of the DNA
glycosyslase MutY homologue (MYH) (Chang and Lu, 2005; Shi et al., 2006) and
apurinic/apyrimidinic endonuclease 1 (Gembka et al., 2007), which results in the removal
of damaged bases. The 9-1-1 complex also interacts with DNA polymerase β to augment
its activity (Toueille et al., 2004). In addition, the 9-1-1 complex can also bind to flap
endonuclease 1 (Friedrich-Heineken et al., 2005; Wang et al., 2004a) and DNA ligase I
(Smirnova et al., 2005; Wang et al., 2006a), thereby stimulating the cleavage of flaps and
the sealing of the final nick, respectively. Thus the 9-1-1 complex plays an integral role
in the regulation of all of the steps of BER. In addition to regulating BER, members of
the 9-1-1 complex may also regulate homologous recombination repair (HRR), as
knockdown of either Rad9 or Hus1 decreases the efficiency of HRR (Pandita et al., 2006;
Wang et al., 2006b). Moreover, the 9-1-1 complex may also regulate translesion
synthesis in yeast by binding to translesion polymerases (Kai and Wang, 2003;
Sabbioneda et al., 2005). Furthermore, Rad9 and Rad1 possess 3′ to 5′ exonuclease
activity and therefore may facilitate the processing of double-stranded DNA to singlestranded DNA (Bessho and Sancar, 2000; Parker et al., 1998). These results suggest that
the 9-1-1 complex may respond to DNA damage both by activating downstream
signaling pathways and by directly mediating various forms of DNA repair.
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Regulation of Additional Cellular Processes
In addition to regulating the processes described above, members of the 9-1-1
complex have also been shown to play a role in the maintenance of telomeres (Francia et
al., 2006; Nabetani et al., 2004; Pandita et al., 2006). Indeed, this role is evolutionarily
conserved as progressive telomere shortening has been observed in Caenorhabditis
elegans strains that lack Hus1 or MRT-2 (the orthologue of Rad1) (Ahmed and Hodgkin,
2000; Hofmann et al., 2002). Interestingly, Rad9 has been shown to function as a
transcription factor that can transactivate p53 target genes, including p21, which is a well
known regulator of the cell cycle (Yin et al., 2004). Therefore, in addition to playing a
role in checkpoint signaling pathways as a member of the 9-1-1 complex, Rad9 may also
be able to directly affect cell cycle arrest at the G1 to S-phase transition through the
transcriptional activation of p21. In addition to playing a key role in the regulation of
DNA damage checkpoints, Rad9 also has been shown to induce apoptosis through its
interaction with the anti-apoptotic proteins, Bcl-2 and Bcl-xL (Ishii et al., 2005; Komatsu
et al., 2000a; Komatsu et al., 2000b; Yoshida et al., 2002; Yoshida et al., 2003).
Moreover, phosphorylation of Rad9 by either c-Abl (Yoshida et al., 2002) or protein
kinase Cδ (Yoshida et al., 2003) promotes the binding of Rad9 to anti-apoptotic proteins
thereby enhancing apoptosis. Furthermore, Rad9 can be cleaved by caspase-3, resulting
in disruption of the 9-1-1 complex and release of the BH3 domain-containing fragment of
Rad9 into the cytosol where it binds to Bcl-xL to potentiate the apoptotic response (Lee
et al., 2003).
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Defects Resulting from Loss of a Functional 9-1-1 Complex
As described above, the 9-1-1 complex plays an integral role in the regulation of a
multitude of cellular processes including the DDR, DNA repair and apoptosis. Therefore,
disruption of the 9-1-1 complex affects many downstream signaling processes. Impaired
function of the 9-1-1 complex results in defects in cell cycle arrest at both the S and G2/M
checkpoints, an increase in chromosomal abnormalities and increased sensitivity to
genotoxic stresses including topoisomerase poisons, ultraviolet radiation (UV),
hydroxyurea (HU) and ionizing radiation (IR) (Bao et al., 2004; Dang et al., 2005;
Hopkins et al., 2004; Kinzel et al., 2002; Loegering et al., 2004; Pandita et al., 2006;
Roos-Mattjus et al., 2003; Wang et al., 2004b; Wang et al., 2006b; Wang et al., 2003;
Weiss et al., 2000; Weiss et al., 2003). Moreover, loss of Rad9 or Hus1 results in
embryonic lethality, which is, at least in part, attributable to widespread apoptosis during
embryogenesis (Hopkins et al., 2004; Weiss et al., 2000). Although Hus1-/- mouse
embryonic fibroblast (MEF) cells have a cellular proliferative defect, crossing of Hus1+/mice to a p21-/- background results in Hus1-/-p21-/- MEFs that are viable and can be grown
in culture (Weiss et al., 2000). The defects described above emphasize the importance of
the role of the 9-1-1 complex in the regulation of the DDR and cell cycle checkpoints,
maintenance of genomic integrity, proper embryonic development and continued viability
in culture.
While loss of Hus1 has been shown to increase sensitivity to DNA damageinduced cell death, the molecular mechanisms by which this occurs have yet to be
elucidated. In this study, we demonstrate for the first time that loss of Hus1 sensitizes
cells to etoposide treatment through the upregulation of the BH3-only proteins, Bim and
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Puma. Furthermore, loss of Hus1 results in a defect in the binding of Rad9 to chromatin
and release of Rad9 into the cytosol, which in turn enhances the interaction of Rad9 with
Bcl-2 to amplify the apoptotic response.

Programmed Cell Death
The term programmed cell death can be defined as “a genetically controlled celldeath process that is turned on in response to external or internal signals” (Maiuri et al.,
2007b). Programmed cell death has been shown to play an important role in development
by regulating the formation and deletion of structures, controlling cell numbers and
eliminating abnormal and damaged cells (Baehrecke, 2002). For years, the term apoptosis
has been used interchangeably with programmed cell death (Chipuk and Green, 2005;
Edinger and Thompson, 2004). However, accumulating evidence from more recent
studies suggest that several forms of cell death are regulated or “programmed” (Edinger
and Thompson, 2004; Kroemer et al., 2009). Programmed cell death now encompasses
processes such as autophagic cell death and programmed necrosis, in addition to
apoptosis (Degterev and Yuan, 2008; Edinger and Thompson, 2004; Kroemer et al.,
2009; Lockshin and Zakeri, 2004; Okada and Mak, 2004).

Apoptotic Cell Death
Apoptosis is an evolutionarily conserved form of programmed cell death that
results in the self-destruction of a cell. This physiological “cell suicide” program is
essential for development and plays an important role in the regulation tissue
homeostasis, as it allows for the elimination of damaged or redundant cells (Zimmermann
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et al., 2001). Disruption of the apoptotic pathway can lead to the development of
numerous pathological conditions. Increased apoptosis is associated with diseases such as
neurodegenerative disorders, myelodysplastic syndromes, acquired immune deficiency
syndrome and ischemic injury, while impaired apoptosis can lead to cancer and
autoimmune disorders (Thompson, 1995).
Apoptotic cell death is defined by certain morphological and biochemical features
that are distinct from other forms of cell death and include membrane blebbing,
chromatin condensation, nuclear fragmentation, loss of adhesion and cell shrinkage and
the externalization of phosphatidylserine. The resulting apoptotic bodies are removed by
phagocytes, thereby avoiding the initiation of an immune response (Kerr et al., 1972;
Kroemer et al., 2009). Apoptosis is a tightly regulated process that eventually leads to the
activation of cysteinyl aspartate-specific proteases, known as caspases (Nicholson, 1999).
The apoptotic caspases can be separated into two functional groups: the initiator caspases
(caspase-2, -8, -9 and -10) and the effector caspases (caspase-3, -6 and -7). Cleavage of
procaspase zymogens results in their activation allowing them in turn to cleave hundreds
of downstream proteins (Luthi and Martin, 2007). The cleavage of these substrates results
in the biochemical and morphological changes that are associated with apoptotic cell
death (Taylor et al., 2008). Apoptosis is primarily mediated through two pathways: the
extrinsic pathway, which is activated by ligation of death receptors, and the intrinsic or
stress-induced, mitochondrial pathway (Figure 3).
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Figure 3. Overview of the extrinsic and intrinsic apoptotic pathways.

The extrinsic pathway
The extrinsic pathway is activated by the binding of a ligand to its cognate death
receptor. The tumor necrosis factor receptor (TNFR) family consists of more than 20
proteins including TNFR, Fas (CD95 or Apo-1), the TNF-related apoptosis-inducing
ligand (TRAIL), DR3, DR4 (TRAIL-R1) and DR5 (TRAIL-R2), among others
(Ashkenazi, 2002). Members of the TNFR family contain cysteine-rich extracellular
domains and an intracellular death domain (DD). While the extracellular domain is
important for receptor trimerization (which requires the pre-ligand assembly domain) and
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provides ligand specificity, the intracellular death domain is critical for transmitting the
death signal to downstream signaling pathways (Jin and El-Deiry, 2005). Ligand binding
results in receptor activation, which recruits adaptor proteins, such as Fas-associated
death domain (FADD) or TNF-associated death domain (TRADD). The DD of the
receptor binds to the DD of FADD, which exposes the death effector domain (DED) of
FADD. The DED of FADD in turn binds to the DED of procaspase-8 (and procaspase10) to form the death-inducing signaling complex (DISC). Aggregation of procaspase-8
within the DISC leads to autoproteolysis resulting in the activation of caspase-8 and
subsequent cleavage and activation of effector caspases to elicit the apoptotic response
(Ashkenazi, 2002; Jin and El-Deiry, 2005; Zimmermann et al., 2001). In addition to
cleaving downstream effector caspases, caspase-8 has also been shown to cleave Bid; this
truncated form of Bid (tBid) then translocates to the mitochondria to activate the intrinsic
pathway and amplify the apoptotic response (Li et al., 1998; Luo et al., 1998).

The intrinsic pathway
The members of the Bcl-2 family play a central role in the regulation of apoptosis
induced through the intrinsic pathway (Adams and Cory, 2007). The Bcl-2 family
consists of both anti-apoptotic and pro-apoptotic members. Proteins, such as Bcl-2, BclxL, Bcl-w and Mcl-1, are anti-apoptotic and thus prevent activation of apoptosis through
the mitochondrial pathway. Most of these proteins share structural similarity within all
four of the conserved Bcl-2 homology (BH) domains. The pro-apoptotic Bcl-2 family
members can be subdivided into the multi-domain proteins, including Bax, Bak and Bok,
and the BH3-only proteins, which include Bim, Puma, Bid, Bad, BNIP3 and Noxa,
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among others. The multi-domain proteins are structurally similar to the anti-apoptotic
proteins, but lack the BH4 domain, and are essential for inducing apoptosis through the
mitochondrial pathway. The members of the BH3-only family lack structural similarity to
other Bcl-2 family members, except within their BH3 domain. The BH3-only proteins act
as sensors for damage signals and induce apoptosis by neutralizing the anti-apoptotic
proteins or by directly activating the multi-domain, pro-apoptotic proteins of the Bcl-2
family to release apoptogenic factors from the mitochondria (Galonek and Hardwick,
2006; Strasser, 2005). Therefore, the members of the Bcl-2 family ultimately control the
decision of whether a cell is to live or die, based on the relative ratio of anti- to proapoptotic proteins (Cory et al., 2003; Oltvai and Korsmeyer, 1994).
As mentioned above, the BH3-only proteins act as sensors for various stress
stimuli, including cytokine deprivation, hypoxia, oncogene activation and DNA damage,
and are potent inducers of mitochondrial apoptosis (Willis and Adams, 2005). Therefore,
these proteins must be regulated in order to prevent inappropriate activation of apoptosis
and also to ensure that the apoptotic response is fully activated when necessary. It has
been shown that BH3-only proteins can be regulated by a variety of mechanisms,
including transcriptional upregulation, post-translational modification, sequestration to
cytoskeletal components and proteasomal degradation (Puthalakath and Strasser, 2002).
The regulation of the BH3-only proteins is tightly orchestrated and ensures that activation
of Bax/Bak, and thus the intrinsic pathway, occurs only when appropriate.
Activation of the multi-domain proteins is required for mitochondrial outer
membrane permeablization (MOMP), which results in the release of apoptogenic factors
from the mitochondria (Green and Evan, 2002; Reed, 2003). MOMP results in the release
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of cytochrome c into the cytosol where it binds to Apaf-1. Apaf-1 can then oligomerize
and recruit procaspase-9 to form the apoptosome. The clustering of procaspase-9 in the
apoptosome results in the cleavage of procaspase-9 to its active form and subsequent
cleavage and activation of effector caspases. In addition to release of cytochrome c,
MOMP also results in the release of other toxic proteins (Saelens et al., 2004), such as
Smac/Diablo and Omi/Htr2A, which antagonize the inhibitor of apoptosis (IAP) proteins.
The binding of Smac/Diablo and Omi/HtrA2 to IAPs, such as XIAP and cIAP, abrogates
their inhibitory effects on caspases (such as caspase-3 and -9), thus augmenting caspase
activation and the apoptotic response. AIF and endonuclease G are also released from the
mitochondria and aid in DNA fragmentation and chromatin condensation, respectively.
Together, these mitochondrial proteins act in concert to ensure that the apoptotic response
is effectively executed to completion.

DNA Damage-Induced Programmed Cell Death
The intrinsic apoptotic pathway can be triggered by various intracellular and
extracellular stresses including those caused by exposure to DNA-damaging agents, such
as the chemotherapeutic drugs, camptothecin and etoposide (Cory et al., 2003; Reed,
2003). In addition to activating apoptosis, camptothecin and etoposide have also been
shown to activate other forms of programmed cell death, such as autophagy (Abedin et
al., 2007; Shimizu et al., 2004) (see below). Camptothecin and etoposide are two
commonly used chemotherapeutic agents that target topoisomerases to induce DNA
damage. Topoisomerases are a family of enzymes that regulate the topology of DNA by
inducing transient single-strand (topoisomerase I enzymes) or double-strand
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(topoisomerase II enzymes) breaks in DNA to resolve torsional strains (Wang, 2002).
Campothecin and etoposide target topoisomerase I and II, respectively. The cytotoxicity
of these drugs is a result of their ability to stabilize the covalent interaction between a
topoisomerase and DNA, known as the cleavage complex (Montecucco and Biamonti,
2007; Pommier, 2006). Camptothecin and etoposide can both induce single- and doublestrand breaks. When the replication machinery encounters the camptothecintopoisomerase I-DNA complex, topoisomerase I releases the cleaved strand resulting in a
single- and double-strand break in the DNA (Kaufmann, 1998; Pommier, 2006). The
molar ratio between topoisomerase II and etoposide determines whether a single-strand
or double-strand break will be induced (Montecucco and Biamonti, 2007). Thus, both of
these agents are able to elicit a DNA damage response that activates both ATM- and
ATR-mediated signaling to induce apoptosis via the intrinsic apoptotic pathway;
however, the mechanisms by which these topoisomerase poisons induce autophagy are
not well understood.

Autophagic Cell Death
As mentioned above, mechanisms of programmed cell death, such as autophagy,
play an essential role during development. Autophagy is an evolutionarily conserved
process for the bulk degradation of subcellular constituents (Levine and Klionsky, 2004;
Yoshimori, 2004). Evidence is accumulating that suggest that autophagy is involved in a
wide variety of physiological processes and conditions, including aging,
neurodegenerative diseases, infectious diseases and cancer (Kundu and Thompson, 2008;
Levine and Kroemer, 2008; Mizushima et al., 2008) (for a detailed description of
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autophagy see below). Although autophagy is generally thought to play a cytoprotective
role, excess induction of autophagy could result in the digestion of essential proteins and
organelles, thereby promoting the collapse of cellular functions and leading to cell death
(Levine and Yuan, 2005; Tsujimoto and Shimizu, 2005). In addition, it has been
suggested that while cells may preferentially die by activating the apoptotic machinery,
cell death will be induced by any available route, including autophagy, if cells are
exposed to harsh enough conditions (Lockshin and Zakeri, 2004).
Autophagic cell death is morphologically and biochemically different from
apoptotic cell death. Characteristics of autophagic cell death include the absence of
chromatin condensation, massive vacuolization of the cytoplasm, accumulation of
double-membraned vacuoles and little or no uptake by phagocytic cells (Kroemer et al.,
2009). While the expression “autophagic cell death” implies that death is actually
executed by autophagy, it is generally accepted that the term simply describes cell death
with autophagy (Kroemer et al., 2009; Levine and Yuan, 2005). Currently, the direct
causative role of autophagy in cell death remains a key and controversial issue.

Crosstalk between Apoptotic and Autophagic Cell Death
Recent evidence suggests the functional relationship between the apoptotic and
autophagic cell death pathways is quite complex (Maiuri et al., 2007b). Depending on the
stimulus or cellular context, the interplay between autophagy and apoptosis could occur
through several mechanisms: autophagy could induce apoptosis or act in the later stages
of apoptosis to aid in the elimination of apoptotic bodies, autophagy could delay or
prevent apoptosis through the clean-up of damaged mitochondria or the two processes
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may be mutually exclusive, acting as a back-up in case the other pathway fails (Scarlatti
et al., 2009). In addition, common cellular stresses can activate various signaling
pathways that elicit both the induction of autophagy and apoptosis (Maiuri et al., 2007b).
As such, several proteins have been identified that regulate both the autophagic and
apoptotic pathways. Beclin 1 was originally identified through a yeast two-hybrid screen
aimed at identifying novel Bcl-2 and Bcl-xL binding partners (Liang et al., 1999).
Recently, the BH3 domain of Beclin 1, which is required for its interaction with antiapoptotic Bcl-2 family members, has been described, thus Beclin 1 can be classified as a
BH3-only protein (Maiuri et al., 2007a). Furthermore, other BH3-only proteins,
specifically Bad and BNIP3, as well as the pharmacological BH3 mimetic, ABT-737,
were shown to disrupt the interaction between Beclin 1 and Bcl-2/Bcl-xL thereby
stimulating autophagy (Maiuri et al., 2007a). Atg5, a key component of the ubiquitin-like
conjugation system in autophagy (see below), can be cleaved by calpain resulting in the
N-terminal fragment of Atg5 translocating to the mitochondria where it triggers MOMP
(Yousefi et al., 2006). p53, a transcription factor that is known to regulate DNA damageinduced apoptosis, was recently shown to induce DRAM (damage-regulated autophagy
modulator). Knockdown of DRAM not only abrogated the induction of autophagy, but
also inhibited the initiation of apoptosis (Crighton et al., 2006). Other proteins, such as
DAPk (death-associated protein kinase), act as regulators of cell death and can mediate
processes that are involved in both the apoptotic and autophagic pathways including
membrane blebbing (a characteristic of apoptosis) and cytoplasmic vesicle formation (a
characteristic of autophagy) (Inbal et al., 2002). In addition, activation of the DNA
damage-responsive transcription factor, E2F1 results in the upregulation of the
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expression of autophagic proteins, including LC3, Atg1 and Atg5 (Polager et al., 2008).
Thus, numerous proteins play a role in both the apoptotic and autophagic pathways,
which highlights the intricate crosstalk between these two pathways.
In this report, we demonstrate that inhibition of apoptosis, through treatment with
Z-VAD-FMK, results in the induction of caspase-independent cell death in response to
camptothecin treatment. Furthermore, disruption of the 9-1-1 complex, through loss of
Hus1, enhanced DNA damage-induced autophagy. These results suggest that in response
to genotoxic stresses, autophagy may be induced as a cell death mechanism. Surprisingly,
inhibition of autophagy, through knockdown of Atg7 or Bif-1, enhanced cell death in
response to camptothecin treatment, suggesting that the induction of autophagy observed
in Hus1-deficient cells is actually a cytoprotective mechanism. It is of interest to
determine whether the inhibition of caspase activity in these autophagy-deficient cells
would suppress cell death in response to DNA damage.

Autophagy
Autophagy is a tightly regulated process for the bulk degradation of cytoplasmic
constituents (Yoshimori, 2004). This evolutionarily conserved process plays a role in the
maintenance of cellular homeostasis by recycling nutrients and removing damaged
organelles, misfolded proteins and invasive microorgansisms. In addition, recent studies
have shown that autophagy is involved in a variety of physiological processes, including
development, differentiation, tissue remodeling and cell survival, whereas the
deregulation of autophagy has been implicated in the pathogenesis of certain diseases,
such as cancer, cardiomyopathy, muscular diseases and neurodegenerative disorders
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(Kundu and Thompson, 2008; Levine and Klionsky, 2004; Levine and Kroemer, 2008).
At least three distinct types of autophagy have been described; chaperone-mediated
autophagy, microautophagy and macroautophagy (Cuervo, 2004; Klionsky et al., 2007).
The studies included in this report focus on marcroautophagy, hereafter referred to as
autophagy.
Upon the initiation of autophagy, a portion of the cytoplasmic components is
sequestered into cup-shaped membrane structures known as isolation membranes or
phagophores (Levine and Klionsky, 2004). The isolation membrane elongates and the
edges eventually fuse to form a double-membraned vesicle known as an autophagosome.
The autophagosome matures when it fuses with endosomes and lysosomes to become an
autolysosome, within which the enclosed components are degraded by lysosomal
hydrolases. Autophagy occurs at basal levels in virtually all cells, but can be upregulated
in response to environmental changes, such as starvation and exposure to DNA damaging
agents (Crighton et al., 2006; Levine and Kroemer, 2008; Polager et al., 2008; Shimizu et
al., 2004).

Mechanisms that Regulate Autophagy
As mentioned above, the process of autophagy involves multiple steps, including
initiation, cargo selection and packaging, vesicle nucleation, vesicle expansion and
completion, retrieval, docking and fusion and lysosomal degradation of vesicles and their
contents (Levine and Klionsky, 2004). The initiation of autophagy is mainly regulated by
downstream signaling through the target of rapamycin (TOR) and the autophagy-related
(Atg) proteins, including the phosphatidylinositol 3-kinase class III (PI3KC3)-Atg6
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(yeast homologue of mammalian Beclin 1) complex (Levine and Klionsky, 2004; Xie and
Klionsky, 2007) (Figure 4) .
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Figure 4. Model of the mechanisms that regulate autophagy.

ATG genes
Genetic screening in yeast has lead to the discovery of at least 30 autophagyrelated genes, many of which have known orthologues in higher eukaryotes (Klionsky et
al., 2003; Xie and Klionsky, 2007). The corresponding gene products of a subset of the
ATG genes form what has been described as the core autophagy machinery. This
machinery can be subdivided into three main functional groups: (1) the Atg9 cycling
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system, (2) the PI3KC3-Beclin 1 complex and (3) the ubiquitin-like (Ubl) protein system
(Xie and Klionsky, 2007).
Atg9 is one of the most well characterized molecules for the investigation of the
biogenesis of autophagosomes and is the only known transmembrane Atg protein (Noda
et al., 2000). In yeast, Atg9 has been shown to shuttle between perivacuolar sites, known
as phagophore assembly sites (PAS), and peripheral sites which include mitochondria
(Reggiori et al., 2005). In contrast, the mammalian orthologue of Atg9 localizes to the
trans-Golgi network and late endosomes, but not to mitochondria (Yamada et al., 2005;
Young et al., 2006). These results suggest that Atg9-containing vesicles could be a source
of membranes for the biogenesis or expansion of autophagosomes by delivering donor
membranes to the PAS. While the efficient transport of Atg9 to the PAS requires the
Atg9 transport proteins Atg23 and Atg27, the retrieval of Atg9 from the PAS depends on
the Atg1-Atg2-Atg18 complex (Xie and Klionsky, 2007).
Vesicle nucleation is an early step in autophagosome formation and results in the
formation of double-membraned structures. The class III phosphatidylinositol 3-kinase
(PI3KC3), Vps34 (vacuolar protein sorting 34), interacts with Beclin 1 to form a complex
that is required for vesicle nucleation (Volinia et al., 1995). This complex interacts with
p150 (the mammalian homologue of yeast Vps15), a protein kinase that is thought to
activate Vps34 and mediate the binding of the complex to membranes. The Vps34
complex most likely functions at the PAS by recruiting PtdIns(3)P-binding proteins. The
process of autophagosome formation can be blocked by treatment with PI3K inhibitors,
such as 3-MA and wortmannin (Mizushima et al., 2001), suggesting that Vps34 is an
essential regulator of autophagosome formation.
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In addition to the Vsp34-Beclin 1 complex and Atg9, two ubiquitin-like
conjugation systems, Atg12-Atg5 and Atg8-phosphatidylethanolamine (PE), also play a
role in the regulation of autophagic vesicle formation (Ohsumi, 2001). The first system
consists of Atg12 (the ubiquitin-like protein), Atg7 (similar to an E1 ubiquitin-activating
enzyme) and Atg10 (similar to an E2 ubiquitin-conjugating enzyme), which are
responsible for transferring Atg12 to Atg5 (Mizushima et al., 1998; Shintani et al., 1999;
Tanida et al., 1999). This complex then recruits Atg16, which can homooligomerize to
mediate the formation of large protein complexes containing Atg12, Atg5 and Atg16
(Mizushima et al., 2003; Mizushima et al., 1999). The second system is composed of
Atg8 (the ubiquitin-like protein), Atg4 (which cleaves Atg8 exposing a glycine residue
that is then accessible for activation by Atg7), Atg7 (the E1-like protein) and Atg3 (the
E2-like enzyme), which are required for transferring Atg8 to PE (Ichimura et al., 2000;
Kirisako et al., 2000). Unlike the Atg12-Atg5 system, Atg8 conjugation to PE is
reversible through Atg4-mediated cleavage of Atg8 (Kirisako et al., 2000). It has been
shown that the Atg12-Atg5 conjugate is required for the stability and proper localization
of Atg8 (Mizushima et al., 2001; Suzuki et al., 2001). While the Atg12-Atg5 complex
was found to localize to forming autophagosomes and dissociate before vesicle
completion, the Atg8-PE conjugate is located on autophagosomes during their formation
and after completion and is eventually degraded within the autolysosome (Kabeya et al.,
2000; Kirisako et al., 1999; Mizushima et al., 2003; Mizushima et al., 2001).
Accordingly, Atg8 is one of the best markers of autophagosomes and has been used
extensively as an indicator for the initiation of the autophagic pathway and for
autophagosome formation. The mammalian homologue of Atg8, the microtubule24

associated protein light chain 3 (LC3), is modified in a similar mechanism to that of Atg8
(Ichimura et al., 2000; Kabeya et al., 2000). Upon the induction of autophagy LC3 is
cleaved by Atg4 to produce a cytosolic form known as LC3-I. LC3-I is then conjugated
to PE to form LC3-II, which is recruited to the autophagosomal membrane. Thus
examining the modification and localization of LC3 are well described methods to
monitor the induction of autophagy (Mizushima and Yoshimori, 2007; Tasdemir et al.,
2008).

Bif-1
Bif-1, also known as Endophilin B1 or SH3GLB1, was originally discovered as a
Bax-interacting protein (Cuddeback et al., 2001; Pierrat et al., 2001). In addition to
regulating apoptosis through its interaction with Bax, Bif-1 has also been found to play
an integral role in the regulation of autophagy. Bif-1 interacts with Beclin 1 through
UVRAG (ultraviolet radiation resistance-associated gene) to promote the activation of
PI3KC3/Vps34 and the formation of autophagosomes (Takahashi et al., 2007).
Furthermore, Bif-1 has an intrinsic ability to induce membrane curvature (Farsad et al.,
2001), suggesting that Bif-1 may collaborate with the Beclin 1-UVRAG-PI3KC3
complex to provide the driving force for the curvature of the isolation membrane. In
response to nutrient starvation, Bif-1 accumulates in foci in the cytosol where it colocalizes with LC3 and Atg5 (Takahashi et al., 2007). As mentioned above, LC3 is a
well-known marker for autophagosomes and Atg5 has been shown to locate to
phagophores throughout the elongation step of autophagosome formation, but is removed
before the completion/sealing of the autophagosome (Kabeya et al., 2000; Klionsky et
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al., 2008; Mizushima et al., 2001). Taken together, these results implicate Bif-1 in the
regulation of the early stages of autophagosome formation and suggest that Bif-1 may
play a role in the biogenesis or expansion of phagophores. Indeed, Bif-1 was found to
localize to Atg9-positive vesicles (Takahashi et al., 2008). As the formation and
trafficking of Atg9-positive vesicles is essential for the biogenesis and expansion of
autophagosomal membranes during the induction of autophagy (Noda et al., 2000;
Young et al., 2006), these results provide further evidence that Bif-1 is involved in these
processes. Further studies are required to determine the precise molecular mechanisms by
which Bif-1 regulates autophagosome formation.

Deregulation of Autophagy in Cancer
Accumulating evidence suggests that autophagy may both enhance and inhibit
tumor development and progression (Mizushima, 2005). In the early stages of tumor
development, tumors are limited in growth by a lack of blood vessels, which provide
necessary oxygen and nutrients. In this setting, induction of autophagy would provide
cells with nutrients in a starvation setting and thus be cytoprotective (Degenhardt et al.,
2006). Alternatively, autophagy could protect cells from undergoing apoptotic cell death
induced by various chemotherapeutic agents (Abedin et al., 2007; Amaravadi et al.,
2007; Carew et al., 2007; Paglin et al., 2001). Conversely, autophagy may hinder tumor
progression by removing damaged or malfunctioning organelles, such as mitochondria,
thereby limiting exposure to genotoxic substances, such as reactive oxygen species,
which would result in enhanced genetic mutations and favor tumorigenesis (Edinger and
Thompson, 2003). Indeed, the concept that autophagy may be beneficial during the early
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stages of tumorigenesis and detrimental during later stages is consistent with the findings
that the rate of autophagy is decreased in malignant pancreatic adenocarcinoma cells as
compared to premalignant cells (Toth et al., 2002).
Recent studies have shown that genetic deregulation of autophagy regulatory
proteins contributes to tumorigenesis. While monoallelic deletions of Beclin 1 are
frequently detected in breast, ovarian and prostate cancers (Aita et al., 1999), monoallelic
mutations in UVRAG occur at a high frequency in colon cancer cells (Ionov et al., 2004).
Furthermore, homozygous deletion of Bif-1 has been confirmed in mantle cell
lymphomas (Balakrishnan et al., 2006) and decreased Bif-1 expression has been
described in gastric carcinomas, colorectal adenocarcinomas, urinary bladder and
gallbladder cancers (Coppola et al., 2008a; Kim et al., 2008; Lee et al., 2006). A recent
study demonstrated that Bif-1 expression is decreased in a significant portion of prostate
cancers, although the majority of prostate cancer samples examined had high levels of
Bif-1 (Coppola et al., 2008b). In addition, Beclin 1+/- and Bif-1-/- mice both have a
significantly enhanced occurrence of spontaneous tumor development (Qu et al., 2003;
Takahashi et al., 2007; Yue et al., 2003) and ectopic expression of UVRAG suppresses
tumorigenesis in nude mice (Liang et al., 2006). Moreover, it was shown that Atg4C and
Atg5 also possess tumor suppressive capabilities (Marino et al., 2007; Yousefi et al.,
2006). In addition to the involvement of autophagy genes in the regulation of
tumorigenesis, it has also been shown that tumor suppressor proteins, such as PTEN, p53
and DAPk, activate autophagy while oncogenes, such as Akt and Bcl-2, suppress
autophagy (Botti et al., 2006). These studies highlight the strong correlation that exists
between proteins that regulate the induction of autophagy and tumor suppression and
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those that inhibit autophagy and oncogenesis (Levine and Kroemer, 2008). While great
strides have been made to determine the connection between the deregulation of
autophagy and cancer, further studies are needed to determine the precise mechanisms by
which autophagy functions in tumorigenesis and tumor suppression. Once the association
between autophagy and cancer has been determined, it will allow for the manipulation of
autophagy to enhance therapeutic treatments for cancer.

Crosstalk between the Autophagic and Endocytic Pathways
The autophagic and endocytic pathways represent branches of the lysosomal
degradation system; these pathways are responsible for the degradation of cytoplasmic
constituents and exogenous substances/macromolecules, respectively. It has been shown
in yeast that two distinct complexes form to regulate these processes; complex I (Vps15,
Vps34, Atg14 and Atg6) and complex II (Vps15, Vps34, Vps38 and Atg6) that are
involved in autophagy and vacuolar protein sorting/endocytosis, respectively (Kihara et
al., 2001). Complex I and II share three common members that are evolutionarily
conserved: the adaptor protein, Vps15 (p150 in mammals), a class III PI3K, Vps34, and
Atg6 (the yeast orthologue of mammalian Beclin 1). Certain members of these complexes
have been shown to play a role in both the autophagic and endocytic pathways, while
others have been found to only be involved in the regulation of one process, but not the
other.
Mammalian Vps34 has been implicated not only in the regulation of autophagy,
but also in endocytic trafficking and sorting of cell-surface receptors and the formation of
internal vesicles in multivesicular endosomes (Backer, 2008). While Vps34 is required
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for the production of PtdIns(3)P for membrane trafficking, particularly at late
endosomes/multivesicular bodies, it is dispensable for the internalization of cell surface
receptors and the uptake of fluid phase markers (Johnson et al., 2006). Another member
of the mammalian Vps34 complex, UVRAG, has been shown to interact with the class C
Vps complex, a key component of the endosomal fusion machinery (Peterson and Emr,
2001), to promote autophagosome maturation by enhancing fusion with late
endosomes/lysosomes (Liang et al., 2008). Similar to Vps34, UVRAG is not involved in
the internalization of endocytic cargo, however it does accelerate intracellular trafficking
and degradation (Liang et al., 2008). In addition, the role of UVRAG in the class C Vps
complex, which regulates endocytic vesicle trafficking, was shown to be distinct from its
role in the Vps34-Beclin 1-Bif-1 complex, which induces autophagy by regulating
autophagosome formation (Liang et al., 2008). Whereas Vps34 and UVRAG both play a
role in the autophagic and endocytic pathways, as mentioned above, Beclin 1 has only
been shown to be required for autophagy and is expendable for endocytosis and vesicle
trafficking (Zeng et al., 2006).
In addition to various proteins being involved in the regulation of both the
autophagic and endocytic pathways, these pathways have been shown to converge at the
prelysosomal and lysosomal level for degradation (Gordon et al., 1992; Gordon and
Seglen, 1988) (Figure 5). Indeed, it has been shown that autophagic vacuoles can directly
fuse with vesicular and multivesicular bodies (MVB) (before fusing with lysosomes) to
form what are known as amphisomes (Fader and Colombo, 2008; Liou et al., 1997).
While much has been discovered about the interplay between the autophagic and
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endocytic pathways, the molecular mechanisms that regulate vesicular trafficking and the
convergence between these two pathways are not fully understood.

Endocytosis

Endosome

Amphisome

Autolysosome

Autophagosome

Degradation

Lysosome

Figure 5. Convergence of the autophagic and endocytic pathways for lysosomal
degradation.

Endocytosis and Vesicle Trafficking
The endocytic pathway functions in cellular homeostasis through the regulation of
internalization, transport, sorting and degradation of macromolecules (Fader and
Colombo, 2008). In addition to a role for endocytosis in vesicle trafficking and
degradation, evidence is accumulating that suggest that endocytosed receptors may be
able to activate specialized signaling complexes that are not assembled at the cell surface
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(Sorkin and Von Zastrow, 2002). Indeed, adaptor and effector proteins have been found
to localize to endosomes containing epidermal growth factor receptors (EGFR) (Di
Guglielmo et al., 1994; Wiley, 2003) and EGFR can maintain signaling even after
internalization and fusion with endosomes (Miaczynska et al., 2004). Therefore, it is
possible that endocytic trafficking could regulate signaling pathways that are distinct
from those initiated at the cell surface (Vieira et al., 1996). Although evidence suggests
that signaling through endocytosis may activate specialized signaling pathways, receptor
endocytosis is generally considered to downregulate growth factor signaling through
lysosomal degradation (Citri and Yarden, 2006).

EGFR as a Model for Endocytic Trafficking and Degradation
The EGFR was one of the first growth factor receptors that was observed to be
internalized following ligand binding (Gorden et al., 1978; Haigler et al., 1979). Based
on extensive studies, which have investigated the mechanisms behind the internalization,
sorting and degradation of this receptor, the EGFR is now a prototype for endocytic
vesicle trafficking (Citri and Yarden, 2006; Sorkin and Von Zastrow, 2002).
Internalization and sorting of the EGFR leads to the removal of activated receptors from
the cell surface. Receptors can then be recycled back to the membrane; alternatively, the
receptors can be degraded, thereby downregulating EGFR-mediated proliferation and
survival signaling (Katzmann et al., 2002) (Figure 6).
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Figure 6. Endcoytic trafficking of the EGFR.
Ligand binding results in EGFR dimerization and phosphorylation, which
provides docking sites that are required for the recruitment of adaptor and effector
proteins that are involved in the regulation of the endocytic pathway (Grandal and
Madshus, 2008). The E3 ubiquitin ligase, Cbl, is recruited to phosphorylated tyrosine
1045 of EGFR (Levkowitz et al., 1999). Cbl-mediated EGFR ubiquitination results in
further recruitment of other signaling molecules and ubiquitin-binding proteins, including
Eps15 and CIN85 (Kirisits et al., 2007), which act as a scaffold for endophilins. Together
these proteins are responsible for inducing the curvature of the plasma membrane and
thus, regulate the formation of clathrin coated pits (Soubeyran et al., 2002). Dynamin
mediates vesicle fission from the plasma membrane, which releases the vesicle into the
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cytoplasm (McNiven et al., 2000). The clathrin then dissociates from the vesicle, which
then fuses with a tubular-vesicular network located at the periphery of the cell. This
fusion results in the delivery of the ligand-bound receptors to early endosomes
(Katzmann et al., 2002; Sorkin and Von Zastrow, 2002). The EGFR is then sorted
through various intracellular trafficking events, which depend on Cbl-mediated ubiquitin
signals (Levkowitz et al., 1998). PI3KC3 is responsible for membrane invagination and
thus the formation of internal vesicles to form MVBs (Futter et al., 2001). The ligandbound receptors then accumulate in the limiting (outer) and lumenal membranes of
MVBs. The limiting membrane then fuses with lysosomal membranes resulting in the
delivery of lumenal contents to the hydrolytic interior of the lysosome where the contents
are then degraded (Futter et al., 1996). In contrast, proteins that remain on the limiting
membrane of MVBs avoid degradation and are subsequently recycled back to the plasma
membrane or transported to other sites within the cell (Katzmann et al., 2002). Thus, the
integrity of the endocytic pathway can be monitored by tracking the fate of activated
EGFR.
In this study, we have found that knockdown of Bif-1 does not affect the uptake
of a fluid phase marker, horse radish peroxidase, or the internalization of epidermal
growth factor (EGF). Interestingly, knockdown of Bif-1 accelerated the co-localization of
internalized EGF with late endosomes/lysosomes. Furthermore, EGFR degradation was
enhanced by loss of Bif-1. These results indicate a novel role for Bif-1 in vesicle
trafficking within the endocytic pathway. Further studies are needed to determine the
molecular mechanisms by which loss of Bif-1 accelerates vesicle trafficking and receptor
degradation.
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Deregulation of Endocytosis in Cancer
Deregulation of EGFR signaling occurs in nearly 50% of all human tumors
(Rodemann et al., 2007). In addition to overexpression and gain-of-function mutations,
the evasion of downregulation by endocytic/lysosomal degradation is another mechanism
that enhances EGFR signaling and drives tumorigenesis (Grandal and Madshus, 2008;
Kirisits et al., 2007; Yarden and Sliwkowski, 2001). Defective downregulation of EGFR
can prolong signaling and thus positively regulate survival and proliferation. Indeed, it
has been shown that preventing the downregulation of EGFR facilitates cell
transformation (Levkowitz et al., 1998). Furthermore, EGFR mutations that impair
ubiquitination and thereby stabilize the EGFR have been described in cancer patients.
These mutations have been shown to protect cells from apoptosis and promote growth
(Grandal and Madshus, 2008). Therefore, elucidating the mechanisms that regulate the
endocytic trafficking and degradation of EGFR could lead to more lucrative therapeutic
approaches for the treatment of cancer.

Summary
As I mentioned above, a functional 9-1-1 complex is required for the maintenance
of genomic stability and thus prevents the accumulation of mutations that could lead to
cancer. Additionally, cells with a disrupted 9-1-1 complex are hypersensitive to
genotoxic stress-induced apoptosis. However, the molecular mechanism by which loss of
a functional 9-1-1 complex activates the apoptotic pathway had yet to be determined. Our
data indicate that loss of Hus1 sensitizes cells to etoposide-induced apoptosis through the
upregulation of Bim and Puma. Furthermore, loss of Hus1 enhances the interaction of
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Rad9 with Bcl-2 to potentiate the apoptotic response. Interestingly, our data suggest that
disruption the 9-1-1 complex not only sensitizes cells to caspase-dependent cell death,
but also to caspase-independent cell death in response to DNA damage. Moreover, the
results presented in this study indicate that loss of Hus1 enhances DNA damage-induced
autophagy. Since excessive induction of autophagy could result in cell death, autophagy
may be the mechanism underlying caspase-independent cell death in Hus1-deficient cells.
However, inhibition of autophagy, by knockdown of Atg7 or Bif-1, enhanced the
cytotoxicity of camptothecin, suggesting that autophagy is being induced as a
cytoprotective mechanism rather than a pro-death mechanism in response to DNA
damage. Finally, our results describe a novel role for Bif-1 in endocytic vesicle
trafficking and receptor degradation. It is therefore likely that Bif-1 promotes survival not
only through its regulation of autophagy, but also by affecting EGFR signaling through
its regulation of the endocytic pathway. Importantly, the results described here better
define the mechanisms that are regulated by the 9-1-1 complex and Bif-1 that affect
sensitivity to DNA damage.
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Chapter Two: Loss of Hus1 Sensitizes Cells to Etoposide-Induced Apoptosis by
Regulating BH3-Only Proteins1

Abstract
The Rad9-Rad1-Hus1 (9-1-1) cell cycle checkpoint complex plays an integral role
in the DNA damage response. Cells with a defective 9-1-1 complex have been shown to
be sensitive to apoptosis induced by certain types of genotoxic stress. However, the
mechanism linking the loss of a functional 9-1-1 complex to the cell death machinery has
yet to be determined. Here, we report that etoposide treatment dramatically upregulates
the expression of the BH3-only proteins, Bim and Puma, in Hus1-deficient cells.
Inhibition of either Bim or Puma expression in Hus1-knockout cells confers significant
resistance to etoposide-induced apoptosis, while knockdown of both proteins results in
further resistance, suggesting that Bim and Puma cooperate in sensitizing Hus1-deficient
cells to etoposide treatment. Moreover, we found that Rad9 collaborates with Bim and
Puma to sensitize Hus1-deficient cells to etoposide-induced apoptosis. In response to
DNA damage, Rad9 localizes to chromatin in Hus1-wild-type cells, whereas in Hus1deficient cells Rad9 is predominantly located in the cytoplasm where it binds to Bcl-2.
Taken together, these results suggest that loss of Hus1 sensitizes cells to etoposideinduced apoptosis, not only by inducing Bim and Puma expression, but also by releasing
Rad9 into the cytosol to augment mitochondrial apoptosis.

1

Meyerkord CL, Takahashi Y, Araya R, Takada N, Weiss RS, Wang HG (2008). Loss of Hus1 sensitizes
cells to etoposide-induced apoptosis by regulating BH3-only proteins. Oncogene 27: 7248-59.
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Results
Loss of Hus1 Sensitizes Cells to Etoposide-Induced Apoptosis
Knockout of Hus1 results in cell cycle checkpoint defects and enhanced cell death
in response to DNA damage induced by hydroxyurea (HU) and ultraviolet (UV) radiation
(Weiss et al., 2000; Weiss et al., 2003; Weiss et al., 2002). In this study, we examine the
sensitivity of Hus1-deficient cells to etoposide, one of the most potent drugs used for
cancer therapy (Montecucco and Biamonti, 2007). In order to determine whether loss of
Hus1 would sensitize cells to etoposide-induced cell death, Hus1+/+p21-/- and Hus1-/-p21-/MEFs were treated with increasing doses of etoposide for 24 h. Measurement of cell
death by trypan blue exclusion assay revealed that knockout of Hus1 greatly enhanced
the dose-dependent susceptibility of MEFs to etoposide (Figure 7a). Consistently, the
hypersensitivity of Hus1-deficient cells to etoposide-induced cell death also occurred in
a time-dependent manner (Figure 7b).
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Figure 7. Loss of Hus1 sensitizes cells to etoposide-induced cell death. (a) Hus1+/+
p21-/- and Hus1-/-p21-/- MEFs were treated with increasing doses of etoposide for 24 h.
Viability was determined by trypan blue exclusion assay (mean ± s.d.; n=3).
(b) Hus1+/+p21-/- and Hus1-/-p21-/- MEFs were treated with 6.25 μg/ml etoposide for
varying time points and subjected to trypan blue exclusion assay (mean ± s.d.; n=3).
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To determine whether the increase in cell death observed in Hus1-deficient cells
is due to the enhanced induction of apoptosis, activation of caspase-3, as well as cleavage
of its downstream substrate, poly(ADP-ribose) polymerase (PARP), were examined by
immunoblot analysis. Hus1-/-p21-/- cells exhibited a robust induction of caspase-3
processing, which correlated with PARP cleavage, upon 24 h treatment with 12.5 μg/ml
etoposide that was further enhanced at a higher dose (Figure 8). In contrast, Hus1+/+p21-/cells showed only slight activation of caspase-3 and minimal PARP cleavage even upon
treatment with the highest dose of etoposide (Figure 8). Induction of apoptosis in
response to etoposide treatment was further analyzed by examination of nuclear
morphology for chromatin condensation and nuclear fragmentation. As shown in Figures
9a and b, Hus1-deficient cells were almost three times more sensitive to etoposideinduced apoptosis. Taken together, these results suggest that MEFs that lack Hus1 are not
only sensitive to hydroxyurea and UV radiation, as previously described, but that these
cells are also sensitive to DNA damage induced by topoisomerase II poisons, such as the
chemotherapeutic drug, etoposide.
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Figure 8. Loss of Hus1 enhances the cleavage of caspase-3 and PARP. Hus1+/+p21-/and Hus1-/-p21-/- MEF cells were treated with varying doses of etoposide for 24 h. Total
cell lysate was normalized for protein content and subjected to SDS-PAGE/immunoblot
analysis.
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Figure 9. Loss of Hus1 sensitizes cells to etoposide-induced apoptosis. (a) Hus1+/+
p21-/- and Hus1-/-p21-/- MEFs were treated with 6.25 μg/ml etoposide for 0 or 48 h.
Apoptosis was determined by examination of nuclear morphology. Arrows indicate
apoptotic nuclei. (b) Hus1+/+p21-/- and Hus1-/-p21-/- MEFs were treated with 6.25 μg/ml
etoposide for the times indicated. The percent of apoptotic cells was quantified based on
nuclear morphology (mean ± s.d.; n=3).

Loss of Hus1 Enhances Bim and Puma Expression at Both the Protein and mRNA Level
in Response to DNA Damage
Since our results indicate that loss of Hus1 sensitizes cells to etoposide-induced
apoptosis, the expression levels of members of the Bcl-2 family were examined (Figure
10). In response to etoposide treatment, the expression levels of anti-apoptotic Bcl-2-like
proteins and pro-apoptotic multi-domain proteins remained relatively stable in both
Hus1+/+p21-/- and Hus1-/-p21-/- MEFs. Notably, the basal level of Bcl-xL was higher in
Hus1-/-p21-/- cells compared to Hus1+/+p21-/- cells, presumably to neutralize elevated Bax
expression in cells lacking Hus1 (Weiss et al., 2000). Interestingly, the expression of the
BH3-only proteins, Bim and Puma, was induced following etoposide treatment. Whereas
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the expression of these proteins was only slightly induced and peaked at 24 h in Hus1wild-type cells, the upregulation of all three isoforms of Bim, as well as Puma, was much
more dramatic and persisted to later time points in Hus1-deficient cells. Similar results
were observed after treatment with other DNA damaging agents including camptothecin,
an inhibitor of topoisomerase I, and hydroxyurea, an inhibitor of DNA replication
(Figures 11 and 12, respectively).
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Figure 10. Expression of Bcl-2 family members in response to etoposide treatment.
Hus1+/+p21-/- and Hus1-/-p21-/- MEFs were treated with 6.25 μg/ml etoposide for the
indicated time points. Total cell lysate was prepared and analyzed by SDSPAGE/immunoblot using the indicated antibodies.
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Figure 11. Loss of Hus1 results in upregulation of Bim and Puma expression in
response to camptothecin treatment. Hus1+/+p21-/- and Hus1-/-p21-/- MEFs were treated
with 500 nM camptothecin (CPT) for the times indicated. Total cell lysate was prepared
and analyzed by SDS-PAGE/immunoblot using the indicated antibodies.
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Figure 12. Loss of Hus1 results in upregulation of Bim and Puma expression in
response to hydroxyurea treatment. Hus1+/+p21-/- and Hus1-/-p21-/- MEFs were treated
with 50 μM hydroxyurea (HU) for the times indicated. Total cell lysate was prepared and
analyzed by SDS-PAGE/immunoblot using the indicated antibodies.
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To confirm that the etoposide-induced upregulation of Bim and Puma expression
is a direct result of loss of Hus1, we examined whether restoration of Hus1 expression
would suppress the induction of these BH3-only proteins in response to etoposide
treatment. To this end, Hus1-/-p21-/- MEFs that were infected with retrovirus to express
either Hus1 (Hus1-/-p21-/- Hus1) or control GFP (Hus1-/-p21-/- GFP) (Weiss et al., 2002)
were treated with etoposide for varying time points and the expression of Bim and Puma
was examined. Expression of Hus1, but not control GFP, significantly reduced etoposideinduced expression of Bim and Puma in Hus1-deficient MEFs (Figure 13). These results
indicate that upregulation of Bim and Puma in response to etoposide-induced DNA
damage is indeed a direct result of loss of Hus1.
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Figure 13. Restoration of Hus1 suppresses the upregulation of Bim and Puma in
response to DNA damage. Hus1-/-p21-/- MEFs stably expressing Hus1 or GFP were
treated with 6.25 μg/ml etoposide for varying time points. Total cell lysate was prepared
and analyzed by SDS-PAGE/immunoblot using the indicated antibodies.
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The activity of BH3-only proteins can be regulated by various mechanisms
including transcriptional upregulation, post-translational modification, proteasomal
degradation and sequestration to cytoskeletal components (Puthalakath and Strasser,
2002; Willis and Adams, 2005). To examine whether the induction of Bim and Puma
expression observed in Hus1-deficient cells is regulated at the transcriptional level after
exposure to etoposide, Hus1-/-p21-/- cells were treated with etoposide in the presence of a
transcriptional inhibitor, actinomycin D, a translational inhibitor, cycloheximide, or
control DMSO. As shown in Figure 14, treatment with either actinomycin D or
cycloheximide abrogated the expression of Bim, as well as Puma, even in the presence of
etoposide. In contrast, the expression of these BH3-only proteins was significantly
induced in response to etoposide treatment in the control DMSO-treated cells (Figure 14),
indicating that upregulation of both Bim and Puma, in response to etoposide-induced
DNA damage, occurs at the transcriptional level. Indeed, semi-quantitative RT-PCR
analyses revealed that the expression of Bim and Puma mRNAs are increased in response
to etoposide treatment (Figures 15-18). The levels of Bim and Puma mRNAs continued
to increase until approximately 24 to 36 h and then decreased at later time points,
presumably due to induction of cell death (Figures 15 and 16). Notably, a greater
upregulation of Bim, especially Bim S, the most potent isoform, and Puma mRNAs was
observed in Hus1-deficient cells, as compared to Hus1-wild-type cells. Consistently,
when cells were treated with a higher dose of etoposide for a shorter time course, a clear
induction of Bim and Puma mRNAs occurred in a time-dependent manner, with more
dramatic increases seen in Hus1-deficient cells (Figures 17 and 18). Notably, the increase
in Bim and Puma protein levels (Figure 10) in Hus1-deficeint cells after etoposide
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treatment is greater than the increase in their mRNA levels (Figures 15 and 16),
suggesting that etoposide-mediated upregulation of Bim and Puma is regulated through
both transcriptional and post-transcriptional mechanisms.
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Figure 14. Induction of Bim and Puma expression in response to etoposide
treatment is regulated at the transcriptional level. Hus1-/-p21-/- MEFs were treated
with control DMSO (-), 1 μg/ml actinomycin D or 5 μg/ml cycloheximide alone or in
combination with 3.125 μg/ml etoposide for 24 h. Total cell lysate was prepared and the
expression of Bim and Puma was analyzed by SDS-PAGE/immunoblot.
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Figure 15. Induction of Bim expression in response to etoposide treatment is
regulated at the mRNA level. Hus1+/+p21-/- and Hus1-/-p21-/- MEFs were treated with
6.25 μg/ml etoposide for 0, 3, 6, 12, 24, 36 or 48 h. (a) Semi-quantitative RT-PCR was
used to examine the mRNA level of Bim. (b, c, d) Quantification of the levels of (b) Bim
EL, (c) Bim L and (d) Bim S.
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Figure 16. Induction of Puma expression in response to etoposide treatment is
regulated at the mRNA level. Hus1+/+p21-/- and Hus1-/-p21-/- MEFs were treated with
6.25 μg/ml etoposide for 0, 3, 6, 12, 24, 36 or 48 h. (a) Semi-quantitative RT-PCR was
used to examine the mRNA level of Puma. (b) Quantification of Puma expression.
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Figure 17. Etoposide-induced upregulation of Bim expression occurs at the
transcriptional level. Hus1+/+p21-/- and Hus1-/-p21-/- MEFs were treated with 25 μg/ml
etoposide for 0, 1, 2, 3 or 4 h. Semi-quantitative RT-PCR was used to examine the
mRNA level of Bim.
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Figure 18. Etoposide-induced upregulation of Puma expression occurs at the
transcriptional level. Hus1+/+p21-/- and Hus1-/-p21-/- MEFs were treated with 25 μg/ml
etoposide for 0, 1, 2, 3 or 4 h. Semi-quantitative RT-PCR was used to examine the
mRNA level of Puma.

Since we found that Bim and Puma are regulated, at least in part, at the
transcriptional level, we investigated which transcription factors are responsible for the
upregulation of these BH3-only proteins in response to DNA damage. As it has been
shown that p53 can transcactivate both Bim and Puma in response to DNA damage
(Burns and El-Deiry, 2003; Nakano and Vousden, 2001), we first examined the
possibility that p53 is responsible for the etoposide-induced upregulation of these BH3only proteins. To this end, we examined the effect of loss of p53 on DNA damageinduced Bim and Puma expression by treating Hus1-/- p53-/- and Hus1-/- p21-/- MEFs with
etoposide for varying time points. As shown in Figure 19, loss of p53 resulted in a slight
inhibition of Bim expression and moderate inhibition of Puma expression. However,
knockout of p53 did not affect etoposide-induced cell death or apoptosis, regardless of
Hus1 status (Figures 20 and 21, respectively). Taken together, these results suggest that
p53 is involved in inducing Puma expression and to a lesser extent Bim expression, but
that other factors are also responsible for the induction of Bim and Puma in response to
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etoposide treatment. FoxO3a and E2F1 are also candidates for transcription factors that
may regulate Bim and Puma expression, as both have been shown to upregulate the
expression of these BH3-only proteins in response to DNA damage (Dijkers et al., 2000;
Hershko and Ginsberg, 2004; Sunters et al., 2003; Yang et al., 2006). However,
knockdown of either FoxO3a or E2F1 in Hus1-deficient cells did not inhibit etoposideinduced upregulation of Bim or Puma expression (Figure 22 and 23, respectively). These
results indicate that FoxO3a and E2F1, along with p53, are not essential for the
upregulation of Bim and Puma in response to etoposide treatment in Hus1-deficient cells.
Therefore, further studies are needed to identify the transcription factors that are
responsible for etoposide-induced Bim and Puma expression in cells lacking Hus1.
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Figure 19. Loss of p53 suppresses DNA damage-induced Puma expression. Hus1-/p53-/- and Hus1-/-p21-/- MEFs were treated with 6.25 μg/ml etoposide for the times
indicated. Total cell lysate was prepared and the expression of p53, Bim and Puma were
examined by SDS-PAGE/immunoblot analysis.
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Figure 20. Loss of p53 does not affect etoposide-induced cell death. Hus1+/-p53-/-,
Hus1-/-p53-/-, Hus1+/+p21-/- and Hus1-/-p21-/- MEFs were treated with 6.25 μg/ml etoposide
or control DMSO for 48 h. Cell death was measured by trypan blue exclusion assay. The
data shown represent the percent cell death of etoposide-treated cells minus the percent
cell death of control DMSO-treated cells (mean ± s.d.; n=3).
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Figure 21. Loss of p53 does not affect etoposide-induced apoptosis. Hus1+/-p53-/-,
Hus1-/-p53-/-, Hus1+/+p21-/- and Hus1-/-p21-/- MEFs were treated with 6.25 μg/ml etoposide
for 48 h. The cells were harvested and prepared for TUNEL staining and analysis by flow
cytometry. The data shown represent the percent apoptosis of etoposide-treated cells
minus the percent apoptosis of control DMSO-treated cells (mean ± s.d.; n=3).
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Figure 22. FoxO3a is not responsible for the upregulation of Bim and Puma
expression in response to etoposide treatment. Hus1-/-p21-/- MEFs stably expressing
shRNA targeting FoxO3a or a control scrambled shRNA were treated with 6.25 μg/ml
etoposide for the times indicated. Total cell lysate was prepared and the expression of
FoxO3a, Bim and Puma were examined by SDS-PAGE/immunoblot analysis.
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Figure 23. E2F1 is not responsible for the upregulation of Bim and Puma expression
in response to etoposide treatment. Hus1-/-p21-/- MEFs stably expressing shRNA
targeting E2F1 or a control scrambled shRNA were treated with 6.25 μg/ml etoposide for
the indicated times. Total cell lysate was prepared and the expression of E2F1, Bim and
Puma were examined by SDS-PAGE/immunoblot analysis.
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Knockdown of Bim and Puma Confers Resistance to Etoposide-Induced Apoptosis in
Hus1-Deficient Cells
Our results clearly show that loss of Hus1 not only results in the upregulation of
Bim and Puma expression, but also promotes caspase-3 activation and cell death induced
by etoposide treatment. Since BH3-only proteins play a key role in the initiation of
apoptosis (Huang and Strasser, 2000; Puthalakath and Strasser, 2002; Willis and Adams,
2005), we examined whether the upregulation of Bim and Puma is responsible for
sensitizing Hus1-deficient cells to etoposide treatment. As a dramatic induction of all
three isoforms of Bim was observed in response to etoposide treatment, we first
investigated whether inhibition of Bim expression would suppress DNA damage-induced
cell death in Hus1-/-p21-/- MEFs. Transfection of siRNA specific for Bim abrogated its
expression, even upon treatment with etoposide (Figure 24). Knockdown of Bim
expression resulted in a decrease in PARP cleavage (Figure 24) and partial resistance to
DNA damage-induced cell death (Figure 25), as compared to siGFP or mock transfected
cells. These results suggest that upregulation of Bim expression contributes to the
sensitivity of Hus1-deficient cells to etoposide-induced apoptosis. We next examined
whether the upregulation of Puma expression is also involved in sensitizing Hus1deficient cells to etoposide treatment. To this end, a lentiviral delivery system was used to
transduce Hus1-/-p21-/- MEFs with shRNA targeting Puma or Bim, or a control scrambled
shRNA. Whereas etoposide treatment resulted in the induction of Bim and Puma
expression in control shScrambled expressing cells, the upregulation of these proteins
was suppressed by their respective shRNA (Figure 26). Consistent with the siBim results
shown in Figure 24, expression of shBim suppressed etoposide-induced apoptosis
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(Figures 26 and 27). Moreover, knockdown of Puma expression significantly suppressed
etoposide-induced caspase-3 activation and apoptosis, as compared to control cells
(Figures 26 and 27). Since knockdown of either Bim or Puma alone only partially
suppressed etoposide-induced cell death, we next examined whether Bim and Puma act
redundantly or synergistically to induce apoptosis in response to etoposide treatment. To
this end, shBim expressing Hus1-/-p21-/- MEFs were infected with lentivirus expressing
shRNA targeting Puma, which resulted in efficient knockdown of Puma expression
(Figure 26). Importantly, knockdown of both Bim and Puma resulted in further inhibition
of caspase-3 processing and apoptosis, when compared to Hus1-/-p21-/- cells expressing
shBim or shPuma alone (Figures 26 and 27). Taken together, these results indicate that
Bim and Puma cooperate in sensitizing Hus1-deficient cells to etoposide-induced
apoptosis.
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Figure 24. Knockdown of Bim expression suppresses PARP cleavage in Hus1deficient cells. Hus1-/-p21-/- MEFs were mock transfected or transiently transfected with
siRNA targeting GFP or Bim. Thirty-six hours after transfection, cells were treated with
control DMSO or 6.25 μg/ml etoposide for 30 h. Whole cell lysate was subjected to SDSPAGE/immunoblot analysis with antibodies to PARP (full length PARP is shown), Bim,
Puma and Tubulin. The expression of Bim in DMSO-treated mock transfected cells
represents the basal level of Bim expression.
35

Percent Cell Death

30
25
20
15
10
5
0

Mock

Mock

DMSO

siGFP

siBim

Etoposide

Figure 25. Knockdown of Bim expression confers resistance to etoposide-induced
cell death in Hus1-deficient cells. Hus1-/-p21-/- MEFs were mock transfected or
transiently transfected with siRNA targeting GFP or Bim. Thirty-six hours after
transfection, cells were treated with control DMSO or 6.25 μg/ml etoposide for 30 h.
Viability was determined by trypan blue exclusion assay (mean ± s.d.; n=2). The cell
death of DMSO-treated mock transfected cells represents the basal level of cell death.
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Figure 26. Knockdown of Bim and Puma expression suppresses etoposide-induced
caspase-3 cleavage in Hus1-deficient cells. Hus1-/-p21-/- MEFs were infected with
lentivirus expressing shRNA targeting Bim, Puma, Bim and Puma, or a control
scrambled shRNA (shScram). After selection on puromycin, cells were treated with 12.5
μg/ml etoposide or control DMSO for 16 h. Knockdown of Bim and Puma was
confirmed by SDS-PAGE/immunoblot analysis.
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Figure 27. Knockdown of Bim and Puma expression confers resistance to etoposideinduced apoptosis in Hus1-deficient cells. Hus1-/-p21-/- MEFs stably expressing shRNA
targeting Bim, Puma, Bim and Puma, or a control scrambled shRNA (shScram) were
treated with 12.5 μg/ml etoposide or control DMSO for 16 h. Induction of apoptosis was
measured by caspase-3 activity assay. The caspase-3 activity of control DMSO-treated
cells was subtracted from the amount of caspase-3 activity observed in the etoposide
treated cells. The data are represented as percent relative apoptosis as normalized to the
control infected cells (mean ± s.d.; n=3).

Loss of Hus1 Enhances the Binding of Rad9 to Bcl-2 to Potentiate the Apoptotic
Response
It has been shown that DNA damage promotes the binding of the 9-1-1
checkpoint complex to chromatin to initiate the DNA damage response and facilitate the
activation of downstream proteins (Parrilla-Castellar et al., 2004; Zhou and Elledge,
2000). Consistently, Rad9 binding to chromatin was enhanced in Hus1-wild-type cells in
a time-dependent manner after etoposide treatment (Figure 28). In contrast, chromatin
bound Rad9 was barely detectable in Hus1-deficient cells, although a slight increase was
noticeable after etoposide treatment. These results are consistent with previous findings
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which show that hydroxyurea- and UV-induced binding of Rad9 to the chromatin is
decreased in Hus1-/- cells (Zou et al., 2002). Taken together, these results indicate that
loss of Hus1 results in a defect in the binding of Rad9 to chromatin in response to DNA
damage.
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Figure 28. Loss of Hus1 results in a defect in the binding of Rad9 to chromatin.
Hus1+/+p21-/- and Hus1-/-p21-/- MEFs were treated with 12.5 μg/ml etoposide for 0, 2 or 8
h and subjected to subcellular fractionation. The resulting chromatin bound and soluble
fractions were analyzed by SDS-PAGE/immunoblot using antibodies specific for Rad9
and RPA as a control.
Previous evidence from our laboratory and others demonstrate that Rad9 can
interact with Bcl-2 or Bcl-xL through a BH3-like domain within its N-terminus to
promote apoptosis following DNA damage (Ishii et al., 2005; Komatsu et al., 2000a;
Komatsu et al., 2000b; Lee et al., 2003; Yoshida et al., 2002; Yoshida et al., 2003).
These results indicate that Rad9 not only has functions in the nucleus as a member of a
DNA damage checkpoint complex, but also in the cytosol as an inducer of apoptosis.
Therefore, the effect of loss of Hus1 on the intracellular localization of Rad9 was
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examined. Consistent with previous studies (Burtelow et al., 2000), Rad9 was detected in
both the nuclear and cytosolic fractions of Hus1+/+p21-/- cells when analyzed by
subcellular fractionation (Figure 29). Moreover, etoposide treatment resulted in Rad9
accumulation and hyperphosphorylation in the nucleus of Hus1+/+p21-/- cells (Figure 29).
In contrast, Rad9 was primarily detected in the cytosolic fraction of Hus1-deficient cells
and remained hypophosphorylated even upon DNA damage (Figure 29). These results
suggest that Rad9 chromatin binding and hyperphosphorylation are Hus1-dependent.
Furthermore, immunofluorescent analysis revealed that Rad9 formed punctate nuclear
foci in Hus1-wild-type cells after etoposide treatment, whereas the Rad9 signal
accumulated in perinuclear foci upon treatment with etoposide in Hus1-deficient cells
(Figure 30).
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Figure 29. Rad9 is predominantly detected in the cytosolic fraction of Hus1-deficient
cells. Hus1+/+p21-/- and Hus1-/-p21-/- MEFs were treated with 12.5 μg/ml etoposide or
control DMSO for 12 h and subjected to subcellular fractionation. The resulting cytosolic
(Cyt) and nuclear (Nuc) fractions, along with whole cell lysate (WCL), were analyzed by
SDS-PAGE/immunoblot.
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Figure 30. Rad9 is predominantly located in the cytosol of Hus1-deficient cells.
Hus1+/+p21-/- and Hus1-/-p21-/- MEFs were treated with 12.5 μg/ml of etoposide or control
DMSO for 12 h. Localization of Rad9 was analyzed using fluorescence microscopy.
In order to determine whether Rad9 binds to Bcl-2 family members during
apoptosis, the interaction between Rad9 and Bcl-2 was examined in Hus1+/+p21-/- and
Hus1-/-p21-/- MEFs in response to etoposide treatment. Since the majority of Rad9 was
detected in the cytosolic fraction of Hus1-deficient cells, coimmunoprecipitation of
cytosolic Rad9 with Bcl-2 was performed. While etoposide treatment enhanced Rad9
interaction with Bcl-2, a significant amount of cytosolic Rad9 was bound to Bcl-2 even in
the absence of DNA damage (Figure 31). Thus, it is possible that subcellular
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fractionation using a hypotonic buffer may alter the conformation or localization of Rad9
and Bcl-2, which affects their interaction. Indeed, it has been shown that Rad9 can leak
from the nucleus during subcellular fractionation even in the absence of DNA damage
(Burtelow et al., 2000). In order to confirm the interaction of Rad9 with Bcl-2, the
coimmunoprecipitation was repeated using whole cell lysates. As shown in Figure 32, a
minimal amount of Rad9 was bound to Bcl-2 in the absence of DNA damage, regardless
of Hus1 status. Treatment with etoposide resulted in an induction of Rad9 binding to Bcl2 that was much greater in Hus1-deficient cells as compared to Hus1-wild-type cells.
These results suggest that, in response to DNA damage, Rad9 may also contribute to the
enhanced sensitivity of Hus1-deficient cells through its interaction with anti-apoptotic
Bcl-2 family members.
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Figure 31. Binding of cytosolic Rad9 to Bcl-2 is increased upon treatment with
etoposide and enhanced by loss of Hus1. Hus1+/+p21-/- and Hus1-/-p21-/- MEFs were
treated with 12.5 μg/ml etoposide or control DMSO for 12 h. The cytosolic fractions
were subjected to immunoprecipitation in the presence or absence of anti-Bcl-2
monoclonal antibody. The resulting immunocomplexes were analyzed by SDSPAGE/immunoblot. The amount of Rad9 in the immunocomplexes was quantified and
normalized to cytosolic Rad9. The levels of Bcl-2 bound Rad9 are listed relative to those
of untreated Hus1-/-p21-/- cells, which was set as 1.0.
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Figure 32. Etoposide-induced binding of Rad9 to Bcl-2 is enhanced by loss of Hus1.
Hus1+/+p21-/- and Hus1-/-p21-/- MEFs were treated with 12.5 μg/ml etoposide or control
DMSO for 12 h. Whole cell lysate (WCL) was subjected to immunoprecipitation with
anti-Bcl-2 or control anti-Flag monoclonal antibodies. The resulting immunocomplexes
and WCL were analyzed by SDS-PAGE/immunoblot. The amount of Rad9 in the
immunocomplexes was quantified and normalized to total Rad9. The levels of Bcl-2
bound Rad9 are listed relative to those of untreated Hus1-/-p21-/- cells, which was set as
1.0.
We therefore examined whether Rad9 cooperates with Bim and Puma to sensitize
Hus1-deficient cells to etoposide-induced apoptosis. Hus1-/-p21-/- MEFs stably expressing
shBim and shPuma were infected with lentivirus expressing shRNA targeting Rad9.
Indeed, knockdown of Rad9 resulted in further inhibition of caspase-3 activation, as
compared to the shBim and shPuma expressing cells (Figures 33 and 34). Consistently,
suppression of Rad9 expression in the shBim and shPuma expressing cells conferred
further resistance to etoposide-induced cell death (Figure 35). Taken together, these
results indicate that Rad9 acts in collaboration with Bim and Puma to sensitize Hus1deficient cells to etoposide-induced apoptosis.
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Figure 33. Knockdown of Rad9 further suppresses caspase-3 activation in shBim
and shPuma expressing cells. Hus1-/-p21-/- MEFs stably expressing shBim and shPuma
were infected with lentivirus expressing shRNA targeting Rad9. Cells were treated with
12.5 μg/ml etoposide or control DMSO for 16 h. Knockdown of Rad9, as well as Bim
and Puma, was confirmed by SDS-PAGE/immunoblot analysis.
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Figure 34. Rad9 collaborates with Bim and Puma to sensitize Hus1-deficient cells to
etoposide-induced apoptosis. Hus1-/-p21-/- MEFs stably expressing shBim and shPuma
were infected with lentivirus expressing shRNA targeting Rad9. Cells were treated with
12.5 μg/ml etoposide or control DMSO for 16 h. Induction of apoptosis was measured
using a caspase-3 activity assay.
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Figure 35. Rad9 collaborates with Bim and Puma to sensitize Hus1-deficient cells to
etoposide-induced cell death. Hus1-/-p21-/- MEFs stably expressing control shRNA,
shBim and shPuma, or shBim and shPuma plus shRad9 were treated with 12.5 μg/ml
etoposide for 0, 24 or 48 h. Cell death was determined by trypan blue exclusion assay
(mean ± s.d.; n=3).
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Discussion
In this study, we have demonstrated that loss of Hus1 results in the upregulation
of the BH3-only proteins, Bim and Puma, which is partially responsible for sensitizing
Hus1-deficient cells to etoposide-induced apoptosis. In addition, we found that in the
absence of Hus1, Rad9 functions as a BH3-only protein and cooperates with Bim and
Puma to promote apoptosis in response to etoposide treatment. There are currently two
models for the activation of apoptosis by the Bcl-2 family members: the direct model and
the hierarchy model (Galonek and Hardwick, 2006). The direct model proposes that
BH3-only proteins have varying levels of potency due to their ability to bind various Bcl2-like family members (Certo et al., 2006; Chen et al., 2005; Willis et al., 2007). Thus,
Bim, Puma and tBid are the most potent as they can bind all of the anti-apoptotic Bcl-2
family members, whereas Noxa and Bad are less potent as they can only bind to a subset
of the Bcl-2-like proteins. In the hierarchy model, on the other hand, Bim and Puma, as
well as tBid, are more potent as they act downstream of the other BH3-only proteins and
the Bcl-2-like proteins and can bind directly to the multi-domain pro-apoptotic proteins,
resulting in their activation and the induction of apoptosis (Kim et al., 2006; Kuwana et
al., 2005; Letai et al., 2002). This model suggests that loss of both Bim and Puma would
result in complete inhibition of apoptosis mediated through the intrinsic pathway. Our
results show that knockdown of both Bim and Puma diminishes the hypersensitivity of
Hus1-deficient cells to etoposide-induced apoptosis, indicating that both Bim and Puma
indeed play a central role in the activation of this programmed cell death pathway.
Interestingly, suppression of Rad9 expression in the Bim and Puma double-knockdown
cells resulted in further inhibition of DNA damage-induced apoptosis. Therefore, our data
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argue in favor of the direct model and suggest that it is the ratio of the BH3-only proteins
to the Bcl-2-like proteins that regulates apoptosis.
Our results demonstrate that Bim and Puma mRNA expression is induced by
etoposide treatment. Among known transcription factors, p53, FoxO3a and E2F1 were
the most likely candidates for regulators of Bim and Puma expression in response to
etoposide treatment, as these transcription factors have been shown to upregulate both
Bim and Puma in response to DNA damage (Burns and El-Deiry, 2003; Dijkers et al.,
2000; Hershko and Ginsberg, 2004; Nakano and Vousden, 2001; Sunters et al., 2003;
Yang et al., 2006). However, our results suggest that these transcription factors are not
required for the upregulation of Bim and Puma in Hus1-deficient cells in response to
DNA damage. While we cannot rule out the possibility that loss of p53, FoxO3a or E2F1
results in compensation by other transcription factors, our data indicate that these
transcription factors are not essential for the upregulation of Bim and Puma in response to
etoposide treatment in Hus1-deficient cells. Several other transcription factors have been
shown to regulate BH3-only expression (Shibue and Taniguchi, 2006). It has been
reported that Myc plays a role in the enhanced expression of Bim (Egle et al., 2004).
Additionally, JNK and its downstream pathway, c-Jun/AP-1, have been shown to be
involved in the transcriptional upregulation of Bim (Jin et al., 2006; Putcha et al., 2003;
Whitfield et al., 2001). Furthermore, JNK was reported to phosphorylate p73 at several
residues and this phosphorylation was required for p73-mediated induction of Puma in
response to DNA damage (Jones et al., 2007). It is of interest to determine whether these
proteins are responsible for etoposide-induced Bim and Puma expression in cells lacking
Hus1.
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Rad9 has been shown to play a role in multiple cellular processes including:
regulation of cell cycle checkpoints, transcriptional activation of p53 targets, initiation of
DNA repair and when DNA repair is unfavorable, induction of apoptosis (Lieberman,
2006). It has been suggested that the primary function of Rad9 is to act as a sensor in the
DNA damage response pathway to promote survival by initiating cell cycle arrest and
facilitating DNA repair (Brandt et al., 2006; Loegering et al., 2004). Thus, it is not
surprising that loss of Rad9 sensitizes cells to DNA damage as these cells lack the ability
to activate appropriate cell cycle checkpoints and DNA repair. On the other hand, Rad9
may function as a pro-apoptotic factor in cells with unrepairable, excessively damaged
DNA or a disrupted 9-1-1 complex, such as through loss of Hus1. Hus1-deficient cells
have a defective cell cycle checkpoint, thus making them more sensitive to DNA damage.
In the absence of Hus1, Rad9 was found to be mostly located in the cytosol, where it
formed perinuclear foci and associated with Bcl-2 in response to DNA damage. These
results suggest that loss of Hus1 results in an abrogation of the nuclear functions of Rad9
and an augmentation of its pro-apoptotic functions.
Taken together, the results presented here indicate that the 9-1-1 complex plays a
critical role in the suppression of etoposide-induced apoptosis by regulating the induction
of the BH3-only proteins, Bim and Puma. Loss of Hus1 results in enhanced upregulation
of these BH3-only proteins that initiate mitochondrial apoptosis in response to DNA
damage. Moreover, disruption of the 9-1-1 complex, through loss of Hus1, switches Rad9
from functioning as a mediator of cell cycle checkpoints and DNA repair to an inducer of
apoptosis. Thus, the 9-1-1 complex may act as a checkpoint sensor to decide whether a
cell should survive or undergo apoptosis in response to DNA damage (Figure 36).
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Figure 36. Proposed model for the role of the Rad9-Rad1-Hus1 complex in the
regulation of DNA damage-induced apoptosis. Cells with a functional 9-1-1 complex
can suppress Bim and Puma expression in response to DNA damage, which results in
resistance to apoptosis. In cells with a disrupted 9-1-1 complex, through loss of Hus1,
exposure to DNA damaging agents results in the upregulation of Bim and Puma
expression, which activates the mitochondrial apoptotic pathway. Loss of Hus1 also
results in the cytoplasmic localization of Rad9 and enhances the interaction of Rad9 with
Bcl-2 to potentiate the apoptotic response.
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Materials and Methods
Reagents
Etoposide, camptothecin, hydroxyurea, protease inhibitor cocktail, phosphatase
inhibitor cocktails I and II, cycloheximide and actinomycin D were purchased from
Sigma (St. Louis, MO). Puromycin was purchased from Calbiochem (San Diego, CA).
Antibodies were purchased from the following commercial sources: anti-tubulin, anti-βactin, anti-Flag and FITC-conjugated goat anti-rabbit secondary antibody from Sigma,
anti-Bim and anti-Puma from Calbiochem, anti-Mcl-1 from Rockland Immunochemicals
(Gilbertsville, PA), anti-PARP and anti-cleaved caspase-3 from Cell Signaling (Danvers,
MA), anti-Bcl-2 from BD Pharmingen (San Diego, CA), anti-RPA from Oncogene
(Cambridge, MA), anti-GFP from Clontech (Mountain View, CA), anti-Bak and antiFoxO3a from Upstate (Lake Placid, NY), anti-Bax and goat anti-rabbit IgG-horseradish
peroxidase from Santa Cruz Biotechnology (Santa Cruz, CA). The anti-Rad9 and antiBcl-xL polyclonal rabbit antisera have been previously described (Komatsu et al.,
2000b). Protein G agarose beads, trypan blue and culture medium were purchased from
Invitrogen (Carlsbad, CA). The Nucleofector machine, as well as all Nucleofector
solutions, was purchased from Amaxa Biosystems (Gaithersburg, MD).

Cell Culture, Transfection and Infection
Hus1+/+p21 -/- and Hus1-/-p21-/- cells (Weiss et al., 2000), Hus1-/-p21-/- GFP and
Hus1-/- p21-/- Hus1 cells (Weiss et al., 2002), as well as Hus1+/-p53-/- and Hus1-/-p53-/-cells
(Weiss et al., 2002) were maintained in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal bovine serum, 1.0 mM L-glutamine, 0.1 mM MEM non68

essential amino acids, 100 μg/ml streptomycin and 100 U/ml penicillin. The 21nucleotide siRNA duplexes targeting Bim and GFP were synthesized and purified by
Dharmacon (Lafayette, CO). The siRNA sequence targeting mouse Bim mRNA was 5’AAUCAUGUACAAUCUCUUCAU-3’. The siRNA specific for GFP has previously
been described (Hirai and Wang, 2002). Hus1-/-p21-/- MEFs were transfected with 10 μg
of siRNA per 1 x 106 cells using the Nucleofector system. After transfection, cells were
allowed to recover for 36 h. The medium, containing any cells which may have died due
to transfection, was removed and replaced with treatment medium containing control
DMSO or etoposide.
The pLKO.1-based lentiviral shRNAs targeting Bim (TRCN0000009692), Puma
(TRCN0000009710) and Rad9 (TRCN0000012638) were purchased from Open
Biosystems (Huntsville, AL). The pLKO.1-based scrambled control shRNA vector was
purchased from Sigma (St. Louis, MO). Recombinant lentivirus was produced by cotransfecting the appropriate shRNA plasmid with the ViraPower Packaging Mix
(Invitrogen) into 293FT cells. The resulting supernatant containing shRNA-expressing
lentivirus was used to transduce Hus1-/-p21-/- MEFs according to the manufacturer’s
protocol.

Analysis of Cell Death and Apoptosis
Cell death was assessed by trypan blue exclusion assay. Apoptosis was scored by
the presence of nuclear chromatin condensation and DNA fragmentation and evaluated
by fluorescence microscopy. Briefly, cells were harvested, fixed in 4% paraformaldehyde
for 10 min at room temperature and washed with PBS. Cell nuclei were stained with 0.5
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μg/ml bis-benzimide trihydrochloride (Hoechst 33258, Molecular Probes, Eugene, OR).
At least 200 cells were counted for each sample and percent apoptosis was calculated
[(apoptotic nuclei) / (all nuclei) x 100]. The induction of apoptosis was analyzed using a
Caspase-3 Assay Kit (Sigma), an In Situ Cell Death Detection (TUNEL) kit (Roche
Applied Science, Indianapolis, IN) and by examination of caspase-3 processing and
PARP cleavage by SDS-PAGE/immunoblot analysis.

Semi-Quantitative Reverse Transcription-PCR
Semi-quantitative reverse transcription-PCR was performed using the Qiagen
(Valencia, CA) OneStep RT-PCR system according to the manufacturer’s
recommendations. The primers for Bim and GAPDH have been previously described
(Wong et al., 2005). The primers for Puma are 5’-GTGATCCGGACACGAAGACT-3’
and 5’-GACTCTAAGTGCTGCTGGGC-3’. For quantification, Bim and Puma mRNA
levels were normalized to GAPDH mRNA.

Chromatin Fractionation
Chromatin fractionation was carried out as described previously (Mendez and
Stillman, 2000). Briefly, cells were washed twice with PBS and resuspended in buffer A
(10 mM HEPES, pH 7, 10 mM KCl, 1.5 mM MgCl2, 0.34 M sucrose, 10% glycerol, 1
mM DTT) containing protease inhibitors. Triton X-100 was added to a final
concentration of 0.1% and the cells were incubated for 5 min on ice. The nuclei were
collected by low-speed centrifugation (4 min, 1,500 x g, 4 ºC). The supernatant was
clarified by high-speed centrifugation (15 min, 12,500 x g, 4 ºC) to remove insoluble
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aggregates and the resulting lysate was designated the soluble fraction. The nuclei were
washed once in buffer A and then lysed in buffer B (3 mM EDTA, 0.2 mM EGTA, 1 mM
DTT) with protease inhibitors for 10 min on ice. Insoluble chromatin was collected by
centrifugation at 2,000 x g for 4 min at 4 ºC and washed once in buffer B. The final pellet
was resuspended in 2X Laemmli buffer, boiled for 10 min and used as the chromatin
fraction.

Subcellular Fractionation and Coimmunoprecipitation
Subcellular fractionation was performed as previously described (Wang et al.,
1996). Briefly, cells were washed with PBS then resuspended in hypotonic lysis buffer (5
mM Tris HCl, pH 7.5, 5 mM NaCl, 1.5 mM MgCl2, 0. 1 mM EGTA, 1 mM Na3VO4, 1
mM PMSF, 1 mM DTT, 10 mM NaF, 10 μg/ml aprotinin, 10 μg/ml leupeptin and 10
μg/ml pepstatin A). After incubation on ice for 30 min, cells were homogenized using a
Dounce homogenizer. Samples were spun down at 510 x g for 5 min at 4 °C. The
supernatant (cytosolic fraction) was cleared by centrifugation at 720 x g for 5 min at
4 °C, while the pellet (nuclear fraction) was washed with hypotonic lysis buffer,
centrifuged at 720 x g for 5 min at 4 °C, then lysed in radioimmunoprecipitation assay
buffer.
Coimmunoprecipitation of Rad9 with Bcl-2 was performed as previously
described with minor modifications (Yoshida et al., 2002; Yoshida et al., 2003). Briefly,
whole cell lysate was prepared in 1% NP-40 lysis buffer (50 mM Tris-HCl, pH 7.5, 150
mM NaCl, 1% NP-40, 0.1% SDS, 1 mM Na3VO4, 1 mM PMSF, 1 mM DTT, 10 mM
NaF, 10 μg/ml aprotinin, 10 μg/ml leupeptin and 10μ g/ml pepstatin A). One milligram
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of lysate was precleared by incubation with protein G agarose beads for 1 h at 4 °C. The
precleared lysate was then incubated with anti-Bcl-2 (BD Pharmingen), or anti-Flag
monoclonal antibody as negative control, overnight at 4 °C. The immunocomplexes were
then incubated with protein G agarose beads for 1.5 h at 4 °C. After extensive washing in
lysis buffer, the resulting immunocomplexes were subjected to SDS-PAGE/immunoblot
analysis with anti-Rad9 polyclonal antibody. For coimmunoprecipitation analysis of the
cytosolic fraction, subcellular fractionation was performed as described above, then NP40, SDS and NaCl were added to a final concentration of 1%, 0.1% and 150 mM,
respectively. Coimmunoprecipitation was performed as described above.

Immunofluorescence
Hus1+/+p21 -/- and Hus1-/-p21-/- MEF cells were grown on gelatin-coated glass
coverslips. After treatment with etoposide, cells were washed once with PBS and fixed in
4% paraformaldehyde for 20 min at 4 °C. Cells were then washed three times with PBS
and permeabilized in 0.5% Triton X-100 plus 1% normal goat serum (NGS) for 30 min at
room temperature. After four washes with PBS, the cells were blocked in 5% milk/ 3%
BSA/ 1% NGS for several hours at 4 °C. The cells were then incubated in primary
antibody in blocking solution overnight at 4 °C. After several washes with PBS, cells
were incubated in blocking solution for 30 min at 37 °C, then in FITC-conjugated goat
anti-rabbit secondary antibody for one hour at 37 °C. The cells were washed several
times with PBS before the addition of mounting media containing DAPI (4’, 6’diamidino-2-phenylindole; Vector Laboratories, Burlingame, CA). The fluorescent
images were analyzed using an automated Zeiss Axiovert fluorescence microscope.
72

Chapter Three: Loss of Hus1 Enhances DNA Damage-Induced Caspase-Independent Cell
Death and Autophagy

Abstract
The Rad9-Rad1-Hus1 (9-1-1) complex plays a central role in the decision of
whether a cell should survive or undergo cell death in response to DNA damage.
Although it has been shown that disruption of the 9-1-1 complex sensitizes cells to
certain genotoxic stresses, the precise mechanisms that are responsible for enhanced cell
death are not fully understood. We have recently described the mechanism behind the
sensitivity of Hus1-deficient cells to etoposide-induced apoptosis. Here, we provide
evidence that loss of Hus1 also sensitizes cells to caspase-independent cell death.
Treatment with the pan-caspase inhibitor, Z-VAD-FMK, only moderately inhibited
camptothecin-induced cell death, suggesting that Hus1-knockout cells die through a
caspase-independent mechanism in response to camptothecin-induced DNA damage.
Moreover, we found that loss of Hus1 enhances LC3 foci formation and modification,
indicating that disruption of the 9-1-1 complex enhances DNA damage-induced
autophagy. Interestingly, inhibition of autophagy, by knockdown of Atg7 or Bif-1, does
not suppress, but rather promotes, camptothecin-induced cell death. Taken together, these
results suggest that the 9-1-1 complex plays a key role in the regulation of both caspasedependent and caspase-independent cell death in response to DNA damage and that
autophagy is induced as a survival mechanism when this complex is disrupted.
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Results
Loss of Hus1 Enhances Caspase-Independent Cell Death in Response to DNA Damage
As mentioned above, we have found that disruption of a functional 9-1-1
complex, through loss of Hus1, sensitizes cells to DNA damage-induced cell death
(Meyerkord et al., 2008). Treatment of Hus1-deficient cells with DNA damaging agents
promotes the upregulation of the BH3-only proteins, Bim and Puma, and enhances the
interaction of Rad9 with Bcl-2 thereby inducing the activation of caspase-3 and
apoptosis (Meyerkord et al., 2008). In order to determine if apoptosis is the only
mechanism that sensitizes Hus1-deficient cells to DNA damage-induced cell death,
Hus1+/+p21-/- and Hus1-/-p21-/- MEFs were treated with camptothecin in the presence or
absence of the pan-caspase inhibitor, Z-VAD-FMK. Consistent with a previous report
(Wang et al., 2004b), knockout of Hus1 greatly enhanced the susceptibility of MEFs to
camptothecin-induced cell death (Figure 37). Moreover, the induction of caspase-3
activity observed in Hus1-deficient cells was greater than that in Hus1-wild-type cells
(Figure 38). Whereas caspase-3 was activated in a time-dependent manner in Hus1-wildtype cells, caspase-3 activity increased until the 24 h time point in Hus1-deficient cells,
after which, it decreased presumably due to cell death. Importantly, treatment with ZVAD-FMK completely inhibited the induction of caspase-3 activity, regardless of Hus1
status (Figure 38). Interestingly, the DNA damage-induced cell death observed in Hus1deficient MEFs was only slightly suppressed by addition of Z-VAD-FMK (Figure 37),
suggesting that an alternate cell death mechanism is activated when apoptosis is
inhibited.
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Figure 37. Camptothecin-induced cell death is moderately inhibited by Z-VADFMK. Hus1+/+p21-/- and Hus1-/-p21-/- MEFs were treated with 1 μM camptothecin (CPT)
for 24 or 48 h in the presence or absence of 50 μM Z-VAD-FMK. At the indicated times,
cells were harvested and cell death was determined by trypan blue exclusion assay (mean
± s.d.; n=3).
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Figure 38. Camptothecin-induced caspase-3 activity is abrogated by Z-VAD-FMK.
Hus1+/+p21-/- and Hus1-/-p21-/- MEFs were treated with 1 μM camptothecin (CPT) for the
times indicated in the presence or absence of 50 μM Z-VAD-FMK. At the indicated
times, cells were harvested and the induction of apoptosis was measured by caspase-3
activity assay (mean ± s.d.; n=3).
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Loss of Hus1 Enhances DNA Damage-Induced Autophagy
It has been shown that cells that are resistant to apoptosis initiated through the
mitochondrial pathway, such as those that lack both Bax and Bak (Wei et al., 2001; Zong
et al., 2001), undergo caspase-independent, but autophagy-dependent cell death in
response to DNA damage (Shimizu et al., 2004). Autophagy is an evolutionarily
conserved intracellular process for the bulk degradation of cytoplasmic components that
is initiated in response to environmental changes (Levine and Klionsky, 2004;
Yoshimori, 2004). Although autophagy is generally thought to play a cytoprotective role
by recycling nutrients under starvation conditions and preventing the accumulation of
damaged organelles, excessive autophagy could result in the overconsumption of
functional proteins and organelles, thus leading to cell death (Levine and Yuan, 2005;
Tsujimoto and Shimizu, 2005). In order to examine whether autophagy is involved in the
enhanced caspase-independent cell death observed in Hus1-deficient cells, we established
Hus1+/+p21-/- and Hus1-/-p21-/- MEFs that stably expressed GFP-LC3, a well characterized
marker for autophagy that is used to visualize autophagosomes (Kabeya et al., 2000). In
control DMSO-treated cells, GFP-LC3 was mostly located diffusely throughout the cell;
although, the basal level of GFP-LC3 foci formation was higher in Hus1-deficient cells
(Figure 39). Treatment with rapamycin, which inhibits mTOR to induce autophagy (Noda
and Ohsumi, 1998), resulted in the formation of GFP-LC3 foci in both Hus1-wild-type
and Hus1-deficient MEFs, indicating that both of these cell lines are capable of inducing
autophagy. Interestingly, in response to treatment with either etoposide or camptothecin,
GFP-LC3 foci formation was greatly induced in Hus1-deficient cells, while relatively few
foci were observed in Hus1-wild-type cells (Figure 39). These results suggest that
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autophagy is induced in response to DNA damage and that the level of DNA damageinduced autophagy is enhanced by loss of Hus1. In order to confirm these results, we next
examined the effect of Hus1-deficiency on LC3 modification. During the induction of
autophagy, LC3 is processed from a cytosolic form, LC3-I, to the
phosphatidylethanolamine (PE)-conjugated, membrane-bound form, LC3-II (Kabeya et
al., 2000; Klionsky et al., 2008). Consistent with the results from the analysis of GFPLC3 foci formation, an accumulation of LC3-II was observed in response to etoposide
treatment (Figure 40), indicating that autophagy is indeed being induced in response to
DNA damage. Moreover, the modification of LC3 was much greater in Hus1-deficient
cells, as compared to Hus1-wild-type cells (Figure 40). Taken together, these results
indicate that loss of a functional 9-1-1 complex promotes the induction of DNA damageinduced autophagy.
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Figure 39. Loss of Hus1 enhances DNA damage-induced GFP-LC3 foci formation.
Hus1+/+p21-/- and Hus1-/-p21-/- MEFs stably expressing GFP-LC3 were treated with 12.5
μg/ml etoposide or 500 nM camptothecin for 12 h or 500 nM rapamycin for 3 h. The
localization of GFP-LC3 was examined by fluorescence microscopy.
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Figure 40. DNA damage-induced LC3 modification is enhanced by loss of Hus1.
Hus1+/+p21-/- and Hus1-/-p21-/- MEFs were treated with 6.25 μg/ml etoposide for the times
indicated. Total cell lysate was prepared and the modification of LC3 was examined by
SDS-PAGE/immunoblot analysis.

Autophagy Plays a Cytoprotective Role in Response to DNA Damage
As loss of Hus1 resulted in enhanced autophagy in response to DNA damage, we
next investigated whether autophagy is responsible for sensitizing Hus1-deficient cells to
caspase-independent cell death induced by camptothecin treatment. To this end,
Hus1+/+p21 -/- and Hus1-/-p21-/- MEFs were infected with lentivirus expressing shRNA
targeting Atg7, Bif-1 or a control scrambled shRNA. Both Atg7 and Bif-1 are required
for autophagosome formation and are thus key regulators of the induction of autophagy.
While Atg7 acts as the E1-like enzyme that mediates both of the ubiquitin-like
conjugation systems (Tanida et al., 1999), Bif-1 binds to UVRAG to regulate the
activation of PI3KC3 (Takahashi et al., 2007). As shown in Figure 41, the expression of
Atg7 and Bif-1 was efficiently knocked down in cells stably expressing shAtg7 or shBif79

1, respectively. Consistent with etoposide treatment (Figure 40), LC3 modification was
enhanced in shScrambled-expressing cells after camptothecin treatment (Figure 41).
Similar to a previous study (Komatsu et al., 2005), loss of Atg7 expression completely
abolished the induction of autophagy, as determined by modification of LC3-I to LC3-II
(Figure 41). Moreover, knockdown of Bif-1 significantly suppressed LC3 modification
(Figure 41), as previously reported (Takahashi et al., 2007). Consistently, in response to
camptothecin treatment a greater number of LC3 foci were observed in Hus1-deficient
cells expressing shScrambled (Figure 42). Notably, LC3 foci formation was suppressed
by knockdown of either Atg7 or Bif-1 (Figure 42), suggesting that the initiation of
autophagy is indeed being inhibited in these cells. To determine whether the induction of
autophagy results in cell death in response to DNA damage, we treated the shBif-1,
shAtg7 and control shScrambled-expressing cells with camptothecin and examined cell
death as determined by trypan blue exclusion. Surprisingly, inhibition of autophagy, by
suppression of either Atg7 or Bif-1, significantly enhanced cell death when compared to
shScrambled-expressing control cells (Figure 43). These results suggest that in response
to treatment with DNA damaging agents, autophagy is induced to promote cell survival,
rather than cell death.

80

Hus1+/+ p21-/shScram shAtg7



+



+

Hus1-/- p21-/-

shBif-1 shScram shAtg7



+

+





shBif-1

+ 

+

CPT
Atg7

Bif-1

LC3-I
LC3-II
β-actin

Figure 41. Knockdown of Atg7 or Bif-1 suppresses LC3 modification. Hus1+/+p21-/and Hus1-/-p21-/- MEFs stably expressing shAtg7, shBif-1 or a control scrambled shRNA
(shScram) were treated with treated with 1 μM camptothecin (CPT) for 36 h. Total cell
lysate was prepared and LC3 modification was examined by SDS-PAGE/immunoblot
analysis.
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Figure 42. Knockdown of Atg7 or Bif-1 suppresses DNA damage-induced LC3 foci
formation. Hus1+/+ p21-/- and Hus1-/-p21-/- MEFs stably expressing shAtg7, shBif-1 or a
control scrambled shRNA (shScram) were treated with 500 nM camptothecin (CPT) for
12 h. Immunocytochemistry was used to examine endogenous LC3 localization.
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Figure 43. Inhibition of autophagy results in enhanced cell death in response to
camptothecin treatment. Hus1+/+p21-/- and Hus1-/-p21-/- MEFs stably expressing shAtg7,
shBif-1 or a control scrambled shRNA (shScram) were treated with 1 μM camptothecin
(CPT) for the times indicated. Cell death was determined by trypan blue exclusion assay
(mean ± s.d.; n=3).

The BH3 Mimetic, ABT-737, Does Not Significantly Induce Autophagy
As described above, BH3-only proteins can regulate autophagy by binding to Bcl2 thereby releasing Beclin 1 to induce autophagosome formation and thus the initiation of
autophagy (Liang et al., 1999; Maiuri et al., 2007a). We have shown that the expression
of the BH3-only proteins, Bim and Puma, are dramatically upregulated in Hus1-deficient
cells in response to camptothecin treatment (Meyerkord et al., 2008). In order to
determine whether the upregulation of these BH3-only proteins is the underlying
mechanism behind the enhanced autophagy seen in Hus1-deficient cells, we treated
Hus1+/+p21-/- and Hus1-/-p21-/- MEFs stably expressing GFP-LC3 with the
pharmacological BH3-mimetic, ABT-737. ABT-737 binds to Bcl-2 and Bcl-xL and
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mimics BH3-only protein binding (Oltersdorf et al., 2005), thus releasing Beclin 1 to
induce autophagy (Maiuri et al., 2007a). Therefore, if the excess binding of BH3-only
proteins to Bcl-2-like proteins is the underlying mechanism of enhanced autophagy
induction in Hus1-deficient cells, ABT-737 should promote GFP-LC3 foci formation in
camptothecin-treated Hus1-wild-type cells, such that the GFP-LC3 foci formation in
these cells would be similar to that of Hus1-deficient cells treated with camptothecin
alone. However, co-treatment of ABT-737 and camptothecin resulted in only a slight
induction of autophagy in Hus1-wild-type cells, indicating that upregulation of BH3-only
proteins is not the main mechanism responsible for DNA damage-induced autophagy in
these cells (Figure 44).
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Figure 44. ABT-737 does not significantly enhance GFP-LC3 foci formation.
Hus1+/+p21-/- and Hus1-/-p21-/- MEFs stably expressing GFP-LC3 were treated with 500
nM camptothecin (CPT) in the presence or absence of 10 μM ABT-737 for 12 h. (a) The
localization of GFP-LC3 was examined by fluorescence microscopy. (b) The number of
GFP-LC3 dots per Hus1+/+ p21-/- cell was determined by analyzing images from a
fluorescent microscope.
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Discussion
In the present study, we have demonstrated that the 9-1-1 complex plays an
integral role in the regulation of autophagy and cell death induced by treatment with
DNA damaging agents. Co-treatment of Z-VAD-FMK with camptothecin resulted in
only a moderate inhibition of cell death, regardless of Hus1 status. These results suggest
that DNA damage not only promotes apoptosis, as mentioned previously (Meyerkord et
al., 2008), but also induces a caspase-independent form of cell death when caspase
activity is inhibited. Notably, a greater induction of cell death was observed in
camptothecin-treated Hus1-deficient MEFs as compared to Hus1-wild-type MEFs, even
in the presence of Z-VAD-FMK, indicating that the 9-1-1 complex may play a role in the
suppression of both caspase-dependent and caspase-independent cell death induced by
DNA damage.
In addition to the role of the 9-1-1 complex in the suppression of DNA damageinduced cell death, we have also found that the 9-1-1 complex is responsible for the
suppression of autophagy. DNA damage-induced autophagosome formation was
enhanced when the 9-1-1 complex was disrupted through loss of Hus1. Notably, loss of
Hus1 enhanced the level of autophagosome formation, even in the absence of DNA
damage. Interestingly, it has been shown that Hus1-deficient MEFs have an increased
frequency of spontaneous chromosomal abnormalities and increased expression of DNA
damage-responsive genes (Levitt et al., 2007; Weiss et al., 2000; Zhu and Weiss, 2007).
Therefore, one possible explanation for the enhanced autophagy observed in these cells is
to dispose of mitochondria that have been damaged through activation of the DDR.
Indeed, it has been shown that DNA damage-induced autophagy is involved in the early
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removal of damaged mitochondria (Abedin et al., 2007). Consistent with previous reports
(Abedin et al., 2007; Kanzawa et al., 2004; Katayama et al., 2007; Paglin et al., 2001),
we found that autophagy can be induced after exposure to DNA damaging agents.
Furthermore, while both Hus1-wild-type and Hus1-deficient cells are capable of inducing
autophagy, DNA damage-induced autophagy was enhanced in cells lacking Hus1. It has
also been shown that inhibition of DNA-PK, which plays a major role in the repair of IRinduced double-strand DNA breaks, sensitizes cells to IR through the induction of
autophagy (Daido et al., 2005). Taken together, these results suggest that loss of either
DNA repair machinery or a functional DDR can sensitize cells to DNA damage-induced
autophagy. Alternatively, loss of Hus1 could affect the induction of autophagy by
disrupting signaling upstream of Akt and mTOR. Akt phosphorylation of mTOR results
in the suppression of autophagy induction (Kondo et al., 2005). In addition, it has been
reported that knockdown of ATR prevents Akt activation in response to genotoxic stress
(Caporali et al., 2008). Moreover, Hus1 has been shown to be required for signaling
downstream of ATR (Weiss et al., 2002), suggesting that loss of Hus1 may also disrupt
signaling pathways that are required for the suppression of autophagy. Furthermore,
inhibition of mTOR, by treatment with rapamycin, induced similar levels of autophagy in
both Hus1-wild-type and Hus1-deficient cells. Taken together, these results indicate that
signaling downstream of Akt and mTOR is important for the suppression of autophagy
and that disruption of this signaling, by loss of Hus1, could promote autophagy. While
the precise mechanism linking the 9-1-1 complex to the autophagic machinery has yet to
be determined, our results suggest that this may occur independent of the upregulation of
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BH3-only proteins in Hus1-deficient cells, which conversely was shown to be required
for DNA damage-induced apoptosis (Meyerkord et al., 2008).
Evidence from various studies suggests that autophagy plays a dual role in cell
survival and cell death (Baehrecke, 2005; Tsujimoto and Shimizu, 2005). Indeed, it has
been shown that autophagy is induced in Bax/Bak-/- cells after treatment with etoposide
(Shimizu et al., 2004) and in L929 fibroblast cells treated with Z-VAD-FMK (Yu et al.,
2004). Furthermore, the induction of autophagy observed in these cells is required for cell
death (Shimizu et al., 2004; Yu et al., 2004). In contrast, we found that inhibition of
autophagy, through knockdown of Atg7 or Bif-1, resulted in enhanced cell death in
response to treatment with camptothecin, suggesting that autophagy is induced as a
cytoprotective mechanism in these cells in response to DNA damage. Therefore, it is
possible that autophagy may function as an alternate cell death mechanism only when the
apoptotic pathway is inhibited, such as through loss of Bax/Bak or by treatment with ZVAD-FMK. However, if the apoptotic machinery is intact, such as in shAtg7- and shBif1-expressing Hus1-/-p21-/- cells, DNA damage-induced autophagy may play a prosurvival role. Accumulating evidence now suggests that this may indeed be the case, that
autophagy may act primarily as a survival mechanism by which the cell rids itself of
potentially harmful constituents in order to maintain cellular homeostasis (Kroemer and
Levine, 2008; Levine and Kroemer, 2009). Further studies, in which Hus1-/-p21-/- cells
expressing shAtg7 or shBif-1 are treated with camptothecin in the presence or absence of
Z-VAD-FMK, will be required to determine whether DNA damage-induced autophagy
acts as a cell death or survival mechanism in apoptosis-impaired cells.
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Materials and Methods
Reagents
Etoposide, camptothecin, digitonin, protease inhibitor cocktail and phosphatase
inhibitor cocktails I and II were purchased from Sigma (St. Louis, MO). Z-VAD-FMK
and rapamycin were purchased from Alexis Biochemicals (San Diego, CA). Puromycin
was purchased from Calbiochem (San Diego, CA). Trypan blue and culture medium were
purchased from Invitrogen (Carlsbad, CA). ABT-737 was a kind gift from Abbott
Laboratories. Antibodies were purchased from the following commercial sources: antitubulin, anti-β-actin and FITC-conjugated goat anti-rabbit secondary antibody from
Sigma, anti-LC3 from Novus Biologicals (Littleton, CO) and MBL International (Nakaku Nagoya, Japan), anti-Bif-1 from GeneTex (San Antonio, TX), bovine anti-goat and
bovine anti-mouse IgG-horseradish peroxidase from Santa Cruz Biotechnology (Santa
Cruz, CA) and goat anti-rabbit IgG-horseradish peroxidase from Amersham Biossciences
(Piscataway, NJ). The anti-Atg7 antibody was a generous gift from Dr. Isei Tanida
(Tanida et al., 1999).

Cell Culture, Transfection and Infection
Hus1+/+p21 -/- and Hus1-/-p21-/- MEFs (Weiss et al., 2000) were maintained in
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum, 1.0
mM L-glutamine, 0.1 mM MEM non-essential amino acids, 100 μg/ml streptomycin and
100 U/ml penicillin. To generate the GFP-LC3 expression vector, cDNA encoding a
GFP-LC3 fusion protein was subcloned into the Bgl II-EcoR I site of the pK1-IRES-puro
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vector. Amphotrophic 293T cells were transfected with the GFP-LC3 vector. The
resulting recombinant retrovirus was used to infect Hus1+/+p21 -/- and Hus1-/-p21-/- cells.
The pLKO.1-based lentiviral shRNAs targeting Atg7 (TRCN0000007586) and
Bif-1 (TRCN0000093178) were purchased from Open Biosystems (Huntsville, AL). The
pLKO.1-based scrambled control shRNA vector was purchased from Sigma. The
appropriate shRNA plasmid, along with the ViraPower Packaging Mix (Invitrogen), was
co-transfected into 293FT cells to produce recombinant lentivirus. The supernatant
containing the shRNA-expressing lentivirus was used to infect Hus1+/+p21 -/- and Hus1-/p21-/- cells MEFs according to the manufacturer’s protocol.

Analysis of Cell Death and Apoptosis
Cell death was assessed by trypan blue exclusion assay. The induction of
apoptosis was analyzed using a Caspase-3 Assay Kit (Sigma) according to the
manufacturer’s protocol.

Analysis of LC3 Localization
For analysis of GFP-LC3 localization, Hus1+/+p21 -/- and Hus1-/-p21-/- MEF cells
were grown on gelatin-coated chamber slides. After treatment, cells were washed once
with PBS, then fixed in 3.7% formaldehyde for 7 min at room temperature. The cells
were washed three times with PBS before being mounted with media containing DAPI
(4’, 6’-diamidino-2-phenylindole; Vector Laboratories, Burlingame, CA). The
fluorescent images were obtained using an automated Zeiss Axiovert fluorescence
microscope.
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To examine the localization of endogenous LC3, cells were washed once with
PBS and fixed in 4% paraformaldehyde for 10 min at room temperature. The cells were
then washed three times with PBS and permeabilized in 100 μg/ml digitonin for 15 min
at room temperature. After three washes with PBS, the cells were blocked in 3% BSA for
one hour at room temperature. Cells were then incubated in primary antibody in blocking
solution overnight at 4 °C. After three washes with PBS, cells were incubated in 3%
BSA blocking solution for 30 min, then in FITC-conjugated goat anti-rabbit secondary
antibody for three hours at room temperature. The cells were washed three times with
PBS before the addition of mounting media containing DAPI. The fluorescent images
were analyzed using an automated Zeiss Axiovert fluorescence microscope.

Analysis of LC3 Modification
Modification of LC3 was analyzed by SDS-PAGE/immunoblot. After treatment,
cells were harvested, washed once in ice-cold PBS, then lysed in
radioimmunoprecipitation assay buffer (150 mM NaCl, 10 mM Tris-HCl, 0.1% SDS, 1%
Triton X-100, 1% deoxycholate and 5 mM EDTA pH 8.0) containing protease and
phosphatase inhibitor cocktails. Total cell lysate was subjected to SDSPAGE/immunoblot analysis with anti-LC3 antibody.
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Chapter Four: Knockdown of Bif-1 Accelerates Endocytic Vesicle Trafficking and
Enhances EGFR Degradation

Abstract
The Endophiln proteins are well known regulators of intracellular membrane
dynamics. While the members of the Endophilin A subfamily regulate the formation of
endocytic vesicles at the plasma membrane, members of the Endophilin B subfamily are
involved in regulating the membrane dynamics of organelles, such as the Golgi complex,
mitochondria and autophagosomes. While the mechanisms by which Bif-1/Endophilin B1
regulates membrane dynamics are well studied, the role of Bif-1 in endocytic trafficking
is not well defined. In this study, we report that knockdown of Bif-1 expression does not
affect the uptake of a fluid phase marker, horseradish peroxidase, or the internalization of
EGF. However, loss of Bif-1 results in the premature localization of EGF to late
endosomes/lysosomes. Moreover, knockdown of Bif-1 accelerates the degradation of
EGFR in response to EGF stimulation. We found that EGFR degradation is regulated by
both the lysosomal and proteasomal pathways in Bif-1-knockdown cells. Taken together,
these results identify Bif-1 as a novel regulator of endocytic vesicle trafficking and
receptor degradation.
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Results
Knockdown of Bif-1Does Not Affect Internalization of Endocytic Cargo, but Accelerates
EGF Co-Localization with Late Endosomes/Lysosomes
It has been shown that Bif-1 can interact with Beclin 1 through UVRAG to
promote the activation of PI3KC3/Vps34 and the induction of autophagy (Takahashi et
al., 2007). The activation of Vps34 plays an essential role not only in the regulation of
autophagy, but also in vesicle transport, including endocytic trafficking (Backer, 2008).
As loss of Bif-1 significantly reduces the activity of Vps34, we investigated whether Bif1 also plays a role the regulation of endocytic trafficking. To determine whether loss of
Bif-1 would affect the integrity of the early endocytic pathway, we first examined the
effect of knockdown of Bif-1 expression on the uptake of a fluid phase marker,
horseradish peroxidase (HRP). As shown in Figure 45, knockdown of Bif-1 did not affect
the kinetics of HRP uptake, suggesting that Bif-1 is not involved in the regulation of the
early endocytic pathway and HRP internalization.
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Figure 45. Knockdown of Bif-1 does not affect the internalization of a fluid phase
marker. Wild-type (WT) and Bif-1-knockdown (K/D) HeLa cells were incubated in
uptake media for the times indicated. HRP activity was measured using a 1-Step Turbo
TMB-ELISA kit. Enzyme activity was normalized to protein concentration (mean ± s.d.;
n=3).
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In order to directly investigate the role of Bif-1 in endocytic trafficking, we
examined EGF internalization and endocytic transport to lysosomes. In response to serum
starvation, the EGFR accumulates on the cell surface. After stimulation with EGF, the
EGFR is rapidly activated by phosphorylation of the C-terminal cytoplasmic domain. The
EGF-EGFR complex is then internalized, sorted into multivesicular bodies (MVBs),
delivered to lysosomes and degraded, which efficiently downregulates EGFR signaling
pathways (Katzmann et al., 2002). Therefore, disruptions in the endocytic pathway can
be identified by changes in the localization of the EGF-EGFR complex. As shown in
Figure 46, similar amounts of fluorescently conjugated EGF were initially bound to the
plasma membranes of Bif-1-knockdown cells and control wild-type HeLa cells,
indicating that EGF-receptor binding was not affected by loss of Bif-1. Fifteen minutes
after stimulation the EGF signal formed small foci that were located throughout wild-type
cells. In contrast, the EGF signal accumulated in large aggregates and partially colocalized with LAMP-1, a marker of late endosomes/lysosomes, in Bif-1-knockdown
cells after 15 min of EGF stimulation. Notably, the difference in EGF localization
between Bif-1-knockdown cells and control wild-type cells was more pronounced at 30
min after stimulation. In wild-type cells the EGF signal formed larger foci and began to
co-localize with LAMP-1, whereas the EGF signal was decreased in Bif-1-knockdown
cells, suggesting that the degradation of EGF is accelerated by loss of Bif-1. To
determine if the observed effect of loss of Bif-1 on the endocytic system was due to the
inhibition of autophagy, through knockdown of Bif-1, we established HeLa cells that
stably expressed shRNA targeting Atg5 or a control scrambled shRNA. Atg5 plays a role
in one of the ubiquitin-like conjugation systems and is thus required for autophagosome
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formation and the induction of autophagy (Mizushima et al., 2001). Importantly,
knockdown of Atg5 did not result in an appreciable difference in the localization of EGF
or co-localization with LAMP-1 at any of the times examined (Figure 47), indicating that
inhibition of autophagy does not affect the endocytic trafficking and degradation of EGF.
Taken together, these results describe a novel role for Bif-1 in the regulation of EGF
trafficking to late endosomes/lysosomes through an autophagy-independent mechanism.
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WT

K/D

Figure 46. Knockdown of Bif-1 accelerates the co-localization of EGF with LAMP-1positive vesicles. The localization of Alexa Fluor 488-EGF (green) in wild-type (WT)
and Bif-1-knockdown (K/D) HeLa cells was detected by confocal microscopy. At the
times indicated, the cells were fixed, permeabilized, stained for LAMP-1 (red) and
mounted in media containing DAPI (blue). All images were taken at the same exposure
setting for the 488-EGF signal.
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Figure 47. Knockdown of Atg5 does not affect EGF localization. The localization of
Alexa Fluor 488-EGF (green) in control shScrambled (shScram) or shAtg5-expressing
HeLa cells was monitored by confocal microscopy. At the times indicated, the cells were
fixed, permeabilized, stained for LAMP-1 (red) and mounted in media containing DAPI
(blue). All images were taken at the same exposure setting for the 488-EGF signal.

Knockdown of Bif-1 Promotes EGFR Degradation
Since loss of Bif-1 accelerated the co-localization of EGF to late
endosomes/lysosomes, we next investigated the effect of loss of Bif-1 on the degradation
of EGFR. To this end, we examined the expression of total and phosphorylated EGFR in
response to stimulation with EGF. Indeed, the degradation of EGFR was enhanced by
knockdown of Bif-1 (Figures 48 and 49). Moreover, the rate of degradation of activated
EFGR was markedly accelerated in Bif-1-knockdown cells (Figures 48 and 50),
suggesting that upon EGF stimulation, EGFR-mediated signaling is downregulated more
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rapidly in cells lacking Bif-1. Interestingly, the expression of EGFR before stimulation
with EGF was lower in Bif-1-knockdown cells as compared to control wild-type cells,
suggesting that loss of Bif-1 also affects the stability or turnover of EGFR. Notably,
knockdown of Atg5 did not affect the degradation of total or phosphorylated EGFR
(Figure 51), which is consistent with the EGF localization data (Figure 47). In support of
our results, a recent study has shown that loss of Bif-1 resulted in the premature targeting
of the TrkA receptor to late endosomes and lysosomes, which resulted in the accelerated
the degradation of TrkA (Wan et al., 2008). Taken together, these results suggest that
Bif-1 not only plays a role in autophagy, as previously described, but that Bif-1 also
regulates endocytic vesicle trafficking and the degradation of EGFR.
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Figure 48. Knockdown of Bif-1 enhances EGFR degradation. Wild-type (WT) and
Bif-1-knockdown (K/D) HeLa cells were serum-starved overnight. Cells were incubated
with 100 ng/ml EGF for the times indicated, then washed and harvested. Total cell lysates
were subjected to SDS-PAGE/immunoblot analysis with antibodies specific for total and
phosphorylated EGFR (Tyr 1068).
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Figure 49. Quantification of total EGFR levels and degradation. Cells were treated
and lysate prepared as in Figure 48. Data from three independent experiments were
analyzed (mean ± s.d.). (a) Quantification of total EGFR levels. The levels of EGFR are
listed relative to that of unstimulated wild-type cells, which was set as 1.
(b) Quantification of the percent EGFR relative to time 0 h.
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Figure 50. Quantification of phosphorylated EGFR levels and degradation. Cells
were treated and lysate prepared as in Figure 48. Data from three independent
experiments were analyzed (mean ± s.d.). (a) Quantification of the ratio of phosphoEGFR to total EGFR. (b) Quantification of the percent phospho-EGFR relative to time
0.5 h.
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Figure 51. Knockdown of Atg5 does not affect EGFR degradation. HeLa cells stably
expressing shAtg5 or a control scrambled shRNA were cultured in serum-free DMEM
overnight. Cells were incubated with 100 ng/ml EGF for the times indicated, then washed
and harvested. Total cell lysates were subjected to SDS-PAGE/immunoblot analysis with
antibodies specific for total and phosphorylated EGFR (Tyr 1068).

EGFR Degradation is Mediated through Both Proteasomal and Lysosomal Mechanisms
The degradation of EGFR has been shown to be regulated by both the lysosomal
and proteasomal pathways (Ettenberg et al., 2001; Levkowitz et al., 1999; Levkowitz et
al., 1998; Longva et al., 2002). However, the precise mechanisms that regulate EGFR
degradation are not fully understood. In order to investigate the mechanism by which the
degradation of the EGFR is enhanced by knockdown of Bif-1, we treated Bif-1knockdown and wild-type cells with bafilomycin A1 or MG132, which are well known
inhibitors of the lysosomal and proteasomal pathways, respectively (Lee and Goldberg,
1998; Yoshimori et al., 1991). As shown in Figure 52, treatment with either bafilomycin
A1 or MG132 inhibited the degradation of EGFR. In contrast to a previous study (Alwan
et al., 2003), our results indicated that treatment with bafilomycin A1 does not
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completely inhibit EGFR degradation. Interestingly, the EGFR was still substantially
degraded in Bif-1-knockdown cells, despite treatment with bafilomycin A1 or MG132,
suggesting that the lysosomal and proteasomal pathways may be functionally
compensating for one another. To examine this possibility, Bif-1-wild-type and knockdown cells were treated with either bafilomycin A1 or MG132 alone or in
combination and the degradation of EGFR was examined. Co-treatment of bafilomycin
A1 and MG132 further suppressed the degradation of EGFR as compared to treatment
with either inhibitor alone (Figure 53). These results suggest that the lysosomal and the
proteasomal pathways collaborate to regulate the degradation of EGFR after stimulation
with EGF.
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Figure 52. The lysosomal and proteasomal pathways regulate EGFR degradation.
Wild-type (WT) and Bif-1-knockdown (K/D) HeLa cells were serum-starved overnight,
then treated with 100 ng/ml EGF either alone or in combination with either 250 nM
bafilomycin A1 or 10 μM MG132 for 0, 0.5 or 3 h. The degradation and phosphorylation
of EGFR was examined by SDS-PAGE/immunoblot analysis with antibodies specific for
total and phosphorylated EGFR (Tyr1068).
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Figure 53. The lysosomal and proteasomal pathways collaborate to regulate EGFR
degradation. Wild-type (WT) and Bif-1-knockdown (K/D) HeLa cells were serumstarved overnight then stimulated with 100 ng/ml EGF in the presence of either 250 nM
bafilomycin A1 (Baf) or 10 μM MG132 or a combination of bafilomycin A1 and MG132
for 0, 0.5 or 3 h. The levels of phosphorylated and total EGFR were analyzed by SDSPAGE/immunoblot analysis. (a) Cells were treated with bafilomycin A1 alone or in
combination with MG132. (b) Cells were treated with MG132 alone or in combination
with bafilomycin A1.
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Discussion
In this study, we have described a novel role for Bif-1 in the regulation of
endocytic trafficking and receptor degradation. Our observations indicate that Bif-1 plays
a critical role in the regulation of the later stages of the endocytic pathway with little
affect on internalization. Examination of the levels of both activated and total EGFR, by
SDS-PAGE/immunoblot analysis, revealed that knockdown of Bif-1 enhanced the
degradation of EGFR, especially the activated form. Furthermore, knockdown of Bif-1
lead to the premature targeting of EGF to LAMP-1-positive foci, suggesting that the
accelerated degradation of the EGF-EGFR complex could be the result of precocious
localization to late endosomes/lysosomes. Degradation of the EGFR appears to be
mediated by both lysosomal and proteasomal mechanisms, as co-treatment with
bafilomycin A1 and MG132 resulted in further suppression of EGFR degradation than
treatment with either inhibitor alone. Taken together, our results suggest that although
loss of Bif-1 accelerates intracellular trafficking and receptor degradation, it does not
affect internalization of endocytic cargo. However, further studies are needed to rule out
the possibility that Bif-1 may play a role in vesicular trafficking through the early steps of
the endocytic pathway.
In support of our findings, a recent report described a role for Bif-1 in the
regulation of the endocytic trafficking of nerve growth factor (NGF)-tropomyosin-related
kinase A (TrkA) (Wan et al., 2008). Consistent with our results, Ip and colleagues found
that knockdown of Bif-1 did not affect the internalization of a fluid phase marker;
however, they demonstrated that Bif-1 may regulate the size of early endosomes. In
addition, knockdown of Bif-1 resulted in the premature trafficking of internalized NGF103

TrkA to lysosomes. Furthermore, loss of Bif-1 enhanced the degradation of TrkA and
diminished signaling downstream of NGF-TrkA. Taken together, these studies indicate
that Bif-1 plays a critical role in the regulation of endocytic vesicle trafficking and the
degradation of internalized receptors.
Our laboratory has demonstrated that Bif-1 can interact with Beclin 1 through
UVRAG to promote the activation of PI3KC3/Vps34 (Takahashi et al., 2007). As
mentioned above, the activation of Vps34 plays an critical role not only in the induction
of autophagy, but also in the regulation of vesicle transport, including endocytic
trafficking (Backer, 2008). It has recently been shown that knockdown of Vps34 reduced
the rate of EGFR degradation and disrupted the invagination of late endosomes
preventing the formation of MVBs (Johnson et al., 2006). As Bif-1 has been shown to
promote the activity of Vps34, it would be assumed that loss of Bif-1 should therefore
result in a decrease in endocytic vesicle trafficking and a reduction in EGFR degradation.
However, our results suggest that knockdown of Bif-1 does not suppress, but rather
accelerates, endocytic trafficking and EGFR degradation. One possible explanation for
this discrepancy could be that Bif-1 suppresses these processes by binding to UVRAG
and interrupting the formation of the UVRAG-C-Vps complex as described below.
UVRAG is a Beclin 1-binding protein that regulates the activity of
PI3KC3/Vsp34 and thus the formation of autophagosomes (Liang et al., 2006; Liang et
al., 2007). In addition, a recent report has shown that UVRAG also regulates the
maturation of autophagosomes and the trafficking of endocytic vesicles through its
interaction with the class C Vps complex (Liang et al., 2008). In stark contrast to our
results, which suggest that cells expressing wild-type Bif-1 exhibit delayed EGFR
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degradation as compared to knockdown cells, UVRAG expression was shown to enhance
EFGR localization to endosomes, resulting in the accelerated degradation of EGFR
(Liang et al., 2008). In addition, it was shown that the role of UVRAG in C-Vpsmediated autophagosome/endosome maturation is independent of the role of UVRAG in
Beclin 1-mediated autophagosome formation and maturation (Liang et al., 2008).
Furthermore, Beclin 1 has been shown to exclusively regulate the autophagic pathway,
not endocytic trafficking (Zeng et al., 2006). Taken together, these results suggest that
targeting of UVRAG to the Beclin 1-Bif-1 complex could sequester UVRAG from
interacting with C-Vps, thereby augmenting its role in the autophagic pathway and
abrogating its role in endocytic trafficking. Indeed, Bif-1 has been shown to interact with
the proline rich domain of UVRAG, which is located next to the phospholipid-interacting
C2 domain (Takahashi et al., 2007). The C2 domain of UVRAG, along with the Cterminus, corresponds to the region that is required for the interaction of UVRAG with CVps (Liang et al., 2008). Therefore, it is possible that binding of Bif-1 changes the
conformation of UVRAG which could decrease its affinity for C-Vps and would thus
decrease the maturation and fusion capabilities of UVRAG. Further studies are necessary
to determine whether the expression of a Bif-1 mutant that cannot bind to UVRAG would
affect the localization of UVRAG, its interaction partners and its ability to regulate
endosomal maturation and fusion.
In addition, Bif-1 could also regulate UVRAG localization by tethering UVRAG
to autophagosomes, rather than endosomes. Bif-1 contains an N-BAR domain, which is
required for membrane binding, driving membrane curvature and perhaps regulating
subcellular localization (Masuda et al., 2006). It is therefore possible that Bif-1 may bind
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to UVRAG and regulate its localization thereby targeting UVRAG to autophagosomes,
not endosomes. Therefore, in the absence of Bif-1, UVRAG would be released from
autophagosomes, allowing it to localize to endosomes and regulate the endocytic
pathway. While our results demonstrate that Bif-1 plays an integral role in the later stages
of endocytic trafficking, further studies are needed to determine the molecular
mechanisms by which loss of Bif-1 accelerates EGF trafficking and enhances the
degradation of EGFR.
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Methods and Materials
Reagents
Horseradish peroxidase was from purchased from Sigma (St. Louis, MO). The 1
step-Turbo TMB-ELISA kit was purchased from Pierce (Rockford, IL). Bafilomycin A1
was purchased from Wako Chemicals USA (Richmond, VA). MG132 and puromycin
were purchased from Calbiochem (San Diego, CA). Epidermal growth factor, Alexa
Fluor 488 conjugated EGF, culture medium and penicillin/streptomycin were purchased
from Invitrogen (Carlsbad, CA). Antibodies were purchased from the following
commercial sources: anti-tubulin from Sigma, anti-LAMP-1 from BD Pharmingen (San
Diego, CA), total EGFR and phospho-EGFR from Cell Signaling (Danvers, MA), antiAtg5 from MBL International (Naka-ku Nagoya, Japan), Alexa Fluor 594 chicken antimouse IgG from Invitrogen, bovine anti-mouse IgG-horseradish peroxidase from Santa
Cruz Biotechnology (Santa Cruz, CA) and goat anti-rabbit IgG-horseradish peroxidase
from Amersham Biosciences (Piscataway, NJ).

Cell Culture, Transfection and Infection
Wild-type and Bif-1-knockdown HeLa cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 5% fetal bovine serum, 1.0 mM
L-glutamine, 100 μg/ml streptomycin and 100 U/ml penicillin (Takahashi et al., 2005).
The pLKO.1-based lentiviral shRNA targeting shAtg5 (TRCN0000151963) was
purchased from Open Biosystems. The pLKO.1-based scrambled control shRNA vector
was purchased from Sigma. Recombinant lentivirus was produced by co-transfecting the
appropriate shRNA plasmid with the ViraPower Packaging Mix (Invitrogen) into 293FT
107

cells. The resulting supernatant containing shRNA-expressing lentivirus was used to
infect wild-type HeLa cells according to the manufacturer’s protocol.

Endocytosis of HRP
Analysis of enodcytosis by HRP uptake was performed as previously described
(Johnson et al., 2006; Zeng et al., 2006). Briefly, Bif-1-knockdown and control wild-type
HeLa cells were washed once in DMEM, then incubated with 2 mg/ml HRP in DMEM
containing 1% BSA for the indicated times. Cells were washed three times in ice-cold
PBS containing 1% BSA and once with PBS. Cells were then scraped into PBS and
collected by centrifugation at 400 x g for 4 min at 4ºC. The pellet was washed once with
PBS, then lysed in PBS containing 0.5% Triton X-100 and protease inhibitors. HRP
activity was measured using the 1-Step Turbo TMB-ELISA kit according to the
manufacturer’s protocol. Enzyme activity was normalized to protein concentration.

EGFR Endocytosis and Degradation
To monitor endocytosis, the internalization of EGF coupled to Alexa Flour 488
was examined as previously described (Liang et al., 2008). Briefly, Bif-1-knockdown and
control wild-type HeLa cells were seeded on 2-well chamber slides. The following day,
the cells were washed in DMEM, then cultured in serum-free DMEM overnight in order
to allow the EGFR to accumulate at the cell surface. Cells were washed once in ice-cold
PBS and then incubated in uptake medium (DMEM, 2% BSA and 20 mM HEPES, pH
7.5) containing 5 μg/ml Alexa Fluor 488-EGF for one hour on ice. Unbound ligand was
removed by washing the cells three times in ice-cold PBS. At the indicated times, the
108

cells were fixed in 4% paraformaldehyde for 10 min at room temperature. Cells were
then washed three times with PBS and permeabilized in 100 μg/ml digitonin for 15 min
at room temperature. After three washes with PBS, the cells were blocked for one hour at
room temperature in 3% BSA. Cells were then incubated in primary antibody in blocking
solution overnight at 4 °C. After three washes with PBS, cells were incubated in 3% BSA
blocking solution for 30 min, then in FITC-conjugated goat anti-rabbit secondary
antibody for three hours at room temperature. The cells were washed three times with
PBS before being mounted with media containing DAPI (4’, 6’-diamidino-2phenylindole; Vector Laboratories, Burlingame, CA). The fluorescent images were
obtained using a Leica confocal microscope.
To monitor the degradation of the EGFR, Bif-1-knockdown and control wild-type
HeLa cells were serum-starved overnight. Receptor internalization and degradation were
stimulated by incubating the cells in 100 ng/ml EGF (Invitrogen) in DMEM containing
20 mM HEPES and 0.2% bovine serum albumin at 37 ºC. At the indicated times, cells
were washed once with ice-cold PBS, then collected in lysis buffer (50 mM Tris-HCl, pH
7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 25 mM NaF, 5 mM sodium
pyrophosphate, 1 mM Na3VO4, 2 µg/ml aprotinin, 2 µg/ml leupeptin, 100 µg/ml
phenylmethylsulfonyl fluoride, 1 mM dithiothreitol, 20 mM p-nitrophenyl phosphate, 1%
Triton X-100) as previously described (Ren et al., 2004). Total cell lysates were
subjected to SDS-PAGE/immunoblot analysis with antibodies specific for total and
phosphorylated EGFR (Tyr 1068). The levels of total and phosphorylated EGFR, as well
as degradation, from three independent experiments were quantified by densitometry.
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Scientific Significance
Genomic DNA is constantly being subjected to genotoxic stresses. DNA damage
triggers the activation of complex, highly coordinated DNA damage response (DDR)
pathways, which can initiate cell cycle arrest and promote DNA repair or if DNA repair
is unfavorable, activate the apoptotic machinery to induce cell death (Zhou and Elledge,
2000). Thus the DDR acts as a safeguard to protect genomic integrity and to prevent the
accumulation of mutations which could lead to cancer, as well as other genetic diseases.
A vast amount of data has accumulated that provides insight into the regulation of the
DDR. However, research is still being conducted to elucidate the precise mechanisms by
which DNA damage is sensed and translated into a signal that results in the decision of
whether to arrest the cell cycle or undergo cell death. Further investigation into the
mechanisms that regulate the DDR are imperative, as a better understanding of these
pathways will allow more educated approaches for novel treatment strategies that will
hopefully contribute to the cure of cancer and possibly other diseases.
At the forefront of the DDR is the Rad9-Rad1-Hus1 complex (9-1-1). This
complex is a key mediator of the DDR and regulates many downstream signaling
pathways that are not only involved in cell cycle arrest and DNA repair, but also in the
induction of cell death. It is well accepted that the 9-1-1 complex confers resistance to a
variety of genotoxic stresses, including several traditional chemotherapeutic agents.
Accordingly, disruption of the 9-1-1 complex has been shown to sensitize cells to DNA
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damaging agents (Hopkins et al., 2004; Kinzel et al., 2002; Loegering et al., 2004; Wang
et al., 2004b; Wang et al., 2006b; Weiss et al., 2000). Importantly, the data presented in
this report describe for the first time the mechanism by which loss of a functional 9-1-1
complex sensitizes cells to etoposide-induced apoptosis. We have shown that etoposide
treatment dramatically upregulates the expression of the pro-apoptotic, BH3-only
proteins, Bim and Puma, in Hus1-deficient cells. The upregulation of these proteins is
responsible for sensitizing Hus1-knockout cells to etoposide-induced apoptosis, as
knockdown of either Bim or Puma confers resistance to etoposide treatment.
Interestingly, knockdown of both Bim and Puma results in further resistance, indicating
that these BH3-only proteins collaborate in sensitizing Hus1-deficient cells to apoptosis
induced by genotoxic stress. Furthermore, loss of Hus1 results in a defect in the binding
of Rad9 to chromatin and release of Rad9 into the cytosol, which enhances the interaction
of Rad9 with Bcl-2 to potentiate the apoptotic response. However, future studies are
necessary to determine the precise mechanisms linking the loss of a functional 9-1-1
complex to the upregulation of Bim and Puma. Taken together, our results clearly
demonstrate a role for the 9-1-1 cell cycle checkpoint complex in the suppression of
genotoxic stress-induced apoptosis and suggest that this complex may play a pivotal role
in determining whether a cell should survive or undergo apoptosis.
Importantly, the results from our studies also reveal a role for the 9-1-1 complex
in the regulation of caspase-independent cell death. Our data indicate that loss of a
functional 9-1-1 complex sensitizes cells to camptothecin treatment, which is only
moderately suppressed by co-treatment with the pan-caspase inhibitor, Z-VAD-FMK.
These results indicate that loss of a functional 9-1-1 complex not only sensitizes cells to
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apoptosis, as described above, but also to caspase-independent cell death when the
apoptotic machinery is inhibited. In addition, we found that loss of Hus1 results in
enhanced autophagy in response to treatment with the DNA damaging agents,
camptothecin and etoposide, suggesting that a functional 9-1-1 complex is required for
suppression of DNA damage-induced autophagy. However, the mechanism by which loss
of a functional 9-1-1 complex activates the autophagic machinery has yet to be
discovered. It has previously been shown that BH3-only proteins, as well as the
pharmacological BH3 mimic, ABT-737, can disrupt the interaction between Bcl-2 and
Beclin 1, which releases Beclin 1 to induce apoptosis. Therefore, it is possible that the
upregulation of BH3-only proteins observed in Hus1-deficienct cells in response to
genotoxic stress could be responsible for enhancing autophagy in these cells. However,
this is unlikely as we found that co-treatment of Hus1-wild-type cells with ABT-737 and
camptothecin did not significantly enhance DNA damage-induce autophagy. These
results suggest that the mechanism by which loss of Hus1 induces autophagy occurs
independent of the upregulation of BH3-only protein expression.
As loss of Hus1 both enhanced caspase-independent cell death and the initiation
of autophagy in response to DNA damage, we predicted that the induction of autophagy
was responsible for the caspase-independent cell death observed in Hus1-knockout cells.
Interestingly, inhibition of autophagy, through knockdown of Atg7 or Bif-1, did not
suppress, but rather enhanced DNA damage-induced cell death in Hus1-deficient cells.
These results indicate that the induction of autophagy observed in Hus1-knockout cells
may play a cytoprotective role. Interestingly, damaged mitochondria, which could release
apopotogenic factors and activate the caspase cascade, have been shown to be removed
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by autophagy (Abedin et al., 2007; Mijaljica et al., 2007). Therefore, it is not difficult to
imagine that inhibition of the clearance of damaged mitochondria by suppressing
autophagy could amplify the apoptotic response. It is of interest to determine whether
prevention of caspase activation (e.g. by treatment with Z-VAD-FMK) could suppress
cell death when the induction of autophagy is inhibited. Taken together, our results
highlight a role for the 9-1-1 complex in the regulation of various cell death mechanisms
and suggest that targeting the 9-1-1 complex may be an effective treatment strategy for
cancer, even in cells with impaired apoptosis (see below).
While an immense amount of research has focused on investigating the role of the
9-1-1 complex in the DDR, much less is known about the role of the 9-1-1 complex in
cancer progression. Interestingly, overexpression of members of the 9-1-1 complex has
been observed in various types of cancer, including breast cancer, non-small cell lung
carcinoma and prostate cancer (Cheng et al., 2005; de la Torre et al., 2008; Maniwa et
al., 2005; Zhu et al., 2008). Moreover, high Hus1 expression in ovarian tumors was
found to correlate with poor prognosis and advanced stage (de la Torre et al., 2008). In
addition, aberrantly high levels of Rad9 mRNA in breast cancer cells were associated
with tumor size and local recurrence, suggesting that Rad9 overexpression may play a
role in tumor proliferation and local invasion (Cheng et al., 2005). Consistently, Rad9
protein abundance has been shown to strongly correlate with advanced stage prostate
cancer and knockdown of Rad9 led to decreased tumorigenicity in nude mice (Zhu and
Lieberman 2008). The concept that overexpression of Rad9 enhances tumorigenesis may
seem contradictory given the well-described role of Rad9 in apoptosis (Ishii et al., 2005;
Komatsu et al., 2000a; Komatsu et al., 2000b; Yoshida et al., 2002; Yoshida et al., 2003).
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However, as Rad9 was found to accumulate in the nucleus of non-small cell lung
carcinoma cells (Maniwa et al., 2005), it is not unreasonable to assume that
overexpression of members of the 9-1-1 complex could result in enhanced complex
formation and retention of the complex in the nucleus. Enforced nuclear localization
would augment the nuclear functions of Rad9, such as activation of cell cycle
checkpoints and initiation of DNA repair, and abrogate the cytosolic functions of Rad9 in
activating the apoptotic machinery. It is reasonable to assume that rapidly dividing cancer
cells may benefit from, or even require, additional DNA repair mechanisms (e.g. elevated
expression of DDR proteins, such as Rad9 and Hus1) in order to offset the high level of
DNA replication and the corresponding DNA damage that can occur during this process.
Alternatively, the increase in DNA repair mechanisms could provide resistance by
rapidly and efficiently repairing DNA damage incurred by exposure to chemotherapeutic
agents. Thus, overexpression of members of the 9-1-1 complex could provide cancer cells
with a survival advantage and resistance to chemotherapy thereby enhancing
tumorigenicity.
As described above, evidence is accumulating that suggests that overexpression of
members of the 9-1-1 complex promotes tumorigenesis. Conversely, disruption of the 91-1 complex sensitizes cells to commonly used DNA-damaging anticancer agents. In
addition, the 9-1-1 complex plays an apical role in the DDR and a direct role in several
DNA repair pathways. Therefore, the 9-1-1 complex may be a rational target for novel
treatment strategies that would inhibit multiple pathways involved in survival and
resistance to genotoxic stress. Indeed, it has been shown that knockdown of Hus1 in
H1299 non-small cell lung carcinoma cells enhanced the cytotoxicity of cisplatin (Kinzel
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et al., 2002). However, inhibition of the multitude of cellular functions that are regulated
by the 9-1-1 complex could also result in undesirable effects. Ideally, the agent used to
disrupt the 9-1-1 complex would suppress the pro-survival functions of the 9-1-1
complex (e.g. DNA repair) while avoiding unwanted results from inhibition of desired
functions (e.g. apoptosis). Our results indicate that knockout of Hus1 not only disrupts
the binding of Rad9 to chromatin (producing desired effects), but also upregulates BH3only protein expression and enhances the binding of Rad9 to Bcl-2 to augment the
apoptotic response (avoiding undesirable effects). Taken together, these results suggest
that Hus1 may be an optimal target for disruption of the 9-1-1 complex. Alternatively,
agents could be designed that would promote the translocation of Rad9 from the nucleus
to the cytosol, thereby attenuating the nuclear functions of Rad9, such as in the regulation
of DNA repair, and potentiating the cytosolic function of Rad9 as an inducer of
apoptosis. However, the precise mechanisms that regulate the translocation of Rad9 have
yet to be determined, but may involve post-translational modifications, such as
phosphorylation of Rad9 by c-Abl or protein kinase Cδ or cleavage of Rad9 by caspase3. In addition, agents could be designed that would inhibit the interaction between
members of the 9-1-1 complex. However, the effect of using this method to disrupt the 91-1 complex (without decreasing the expression of any of the members) on sensitivity to
DNA damaging agents has yet to be examined. Therefore, additional studies are
necessary to explore this possibility, as this strategy may also be therapeutically
beneficial.
Our results indicate that targeting the 9-1-1 complex would sensitize cells to both
caspase-dependent and caspase-independent cell death in response to treatment with
115

DNA damaging agents. Therefore, disruption of the 9-1-1 complex could efficiently
sensitize cells with impaired apoptotic machinery to commonly used chemotherapeutic
agents. One of the hallmarks of cancer is the ability to evade apoptosis (Hanahan and
Weinberg, 2000). This resistance to apoptotic cell death is an important aspect not only of
tumorigenesis, but also the development of resistance to anticancer drugs (Green and
Evan, 2002; Hanahan and Weinberg, 2000). As such, a large area of research focuses its
efforts on the restoration of apoptosis in cancer cells (Reed, 2006; Wang and El-Deiry,
2008). Importantly, a growing body of evidence indicates that autophagy may act as a
cell death mechanism in cells with impaired apoptotic machinery (Shimizu et al., 2004;
Yu et al., 2004). Therefore, rather than trying to restore apoptotic machinery, a more
lucrative approach may be to disrupt the 9-1-1 complex and activate autophagy in these
cells in order to manipulate the cell’s ability to induce alternate forms of cell death.
Indeed, several commonly used chemotherapeutic agents have been shown to induce
autophagy (Kondo et al., 2005) and could potentially be used in combination with
disruption of the 9-1-1 complex to sensitize cells that are resistant to apoptosis. However,
this strategy may only be feasible in apoptosis-deficient cells, as our results and those of
other laboratories suggest that autophagy can promote survival in cells that are apoptosiscompetent (Kroemer and Levine, 2008). In apoptosis-competent cells, an alternate
approach could be to inhibit autophagy and disrupt the 9-1-1 complex in order to enhance
apoptotic cell death in response to chemotherapy. While recent studies have provided
insight into the interplay between the autophagic and apoptotic pathways and how this
may affect sensitivity to chemotherapy, future studies are needed to further define the
crosstalk between these two cell death mechanisms. Once this knowledge is obtained,
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controlling the balance between apoptotic and autophagic cell death could lead to
enhanced tumor cell killing and thus provide more efficient cancer treatments.
Another strategy for enhancing the cytotoxicity of anticancer agents would be to
inhibit certain functions of Bif-1, in combination with disruption of the 9-1-1 complex. In
this report, we demonstrate that knockdown of Bif-1 significantly enhances
camptothecin-induced cell death in Hus1-deficient cells. However, our results indicate
that knockdown of Bif-1 expression suppresses, but does not completely block the
induction of autophagy. These results suggest that while Bif-1-mediated autophagy may
protect cells from DNA damage-induced cell death, other functions of Bif-1 may also
play a role in the suppression of cell death. In this study, we describe a novel role for Bif1 in the regulation of endocytic vesicle trafficking and receptor degradation. While
knockdown of Bif-1 did not affect the internalization of either a fluid phase marker or
EGF, it accelerated the co-localization of EGF with late endosomes/lysosomes and
enhanced the degradation of activated EGFR. As knockdown Bif-1 enhances the
degradation of EGFR, it can be assumed that inhibition of Bif-1 function could result in
the rapid attenuation of EGFR signaling. Therefore, suppression of Bif-1 function in
cancer cells with hyperactivated EGFR signaling may be a potentially beneficial
therapeutic strategy. However, as loss of Bif-1 has been shown to significantly enhance
spontaneous tumorigenesis in mice (Takahashi et al., 2007), care should be taken when
designing therapeutics that target Bif-1. In addition to the newly described role of Bif-1
in endocytic vesicle trafficking, our laboratory has also shown that Bif-1 is involved in
the regulation of Bax-mediated apoptosis and the induction of autophagy (Cuddeback et
al., 2001; Takahashi et al., 2007; Takahashi et al., 2005). Therefore, in order to properly
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target Bif-1 for anticancer therapy, the specific functions of Bif-1 that are responsible for
its tumor suppressive capabilities and the functions that are required for regulating
sensitivity to DNA damage-induced cell death must first be defined. This knowledge
could then be used for the rational design of anticancer agents that would specifically
target the pro-survival functions of Bif-1 while leaving the anti-tumor functions intact.
Given that both autophagy and EGFR signaling have been shown to promote survival, the
role of Bif-1 in these processes may be the most likely candidates for conferring
resistance to DNA damage-induced cell death.
Interestingly, it has been suggested that in addition to the various gain-of-function
mutations that occur in the EGFR, deregulation or inefficient EGFR degradation may
also play a significant role in the aberrant activation of EGFR signaling thereby
enhancing tumor development (Grandal and Madshus, 2008; Kirisits et al., 2007). As
EGFR signaling has been shown to persist even within endosomes (Miaczynska et al.,
2004; Sorkin and Von Zastrow, 2002), enhanced EGFR degradation, by inhibition of Bif1 function, could abrogate growth factor-mediated survival signaling through EGFRmediated pathways. In addition, it has been shown that EGFR signaling can be induced in
response to chemotherapy and exposure to ionizing radiation, even in the absence of
ligand binding (Rodemann et al., 2007). EGFR that is activated in such a manner has
been shown to confer resistance to DNA damaging chemotherapeutic agents by
activating various mechanisms that efficiently repair damaged DNA, thereby
counteracting the cytotoxic effects of the chemotherapy. Therefore, targeting Bif-1
functions in endocytic vesicle trafficking may have similar effects to current therapeutic
approaches that inhibit EGFR signaling. Indeed, it has been shown that inhibiting EGFR
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signaling in combination with chemotherapy or radiotherapy results in increased
sensitivity both in preclinical and clinical studies (Nyati et al., 2006).
The results presented in this report suggest that inhibiting Bif-1 function could
potentially target two survival pathways: autophagy and EGFR signaling. In addition, our
results indicate that the combination of inhibition of Bif-1 and disruption of the 9-1-1
complex, through loss of Hus1, enhances the cytotoxicity of camptothecin. These studies
provide evidence supporting the concept that targeting Bif-1 and Hus1 would inhibit
several survival signaling pathways and thus may sensitize otherwise resistant cancer
cells to commonly used chemotherapeutic agents.
In response to genotoxic stress, a complex network of signaling pathways act in
concert to activate the DNA damage response. It is therefore important to determine the
molecular mechanisms that regulate of these signaling pathways in order to improve the
efficacy of cancer treatments. Importantly, the crosstalk between the autophagic and
apoptotic pathways must also be deciphered in order to optimize therapeutic benefits. In
addition to manipulating the interplay between these pathways, other factors such as
those that regulate EGFR endocytic trafficking and degradation, may also prove to be
lucrative targets for sensitizing cancer cells to chemotherapy. Significantly, the results
described in this report offer insight into some of the mechanisms that both sensitize and
provide resistance to DNA damaging agents (Figure 54). Further research will lead to a
better understanding of the molecular mechanisms are regulated by the 9-1-1 complex
and Bif-1 that affect sensitivity to DNA damage and will provide valuable knowledge
that can be used for the rational design of novel chemotherapeutic strategies that will
offer more effective treatments for cancer.
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Functional 9 1 1 complex

Bif-1
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Rad9-Bcl-2
Autophagy

Endocytic vesicle trafficking
Apoptosis

Autophagic cell death

EGFR degradation
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Figure 54. Proposed model for the role of the Rad9-Rad1-Hus1 complex and Bif-1 in
the regulation of sensitivity to DNA damage. A functional 9-1-1 complex confers
resistance to genotoxic stresses by suppressing apoptosis. Loss of Hus1 sensitizes cells to
DNA damage-induced apoptosis through the upregulation of the BH3-only proteins, Bim
and Puma. Moreover, loss of Hus1 enhances the interaction of Rad9 with Bcl-2 to
potentiate the apoptotic response. Loss of Hus1 also enhances DNA damage-induced
autophagy, which promotes survival in apoptosis-competent cells. Inhibiting autophagy
in apoptosis-competent cells may enhance DNA damage-induced apoptosis. Conversely,
inducing autophagy in cells that are apoptosis-impaired may increase the cytotoxicity of
DNA-damaging chemotherapeutic agents. In addition, Bif-1 promotes survival in Hus1deficient cells, perhaps through its regulation of autophagy and/or endocytic vesicle
trafficking (EGFR signaling). Notably, loss of Hus1 sensitizes cells to both caspasedependent and caspase-independent cell death in response to DNA damage.
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